| Excerpt | Reference |
|---|
| "Twenty-six patients with advanced renal cell carcinoma were treated with suramin administered by continuous infusion, with dosing determined by a nomogram." | ( Albino, AP; Bajorin, DF; Iversen, J; Louison, C; Motzer, RJ; Nanus, DM; O'Moore, P; Reuter, V; Scher, HI; Tong, WP, 1992) |
| "This is a rare case of renal cell carcinoma with local recurrence and lung metastasis successfully treated with UFT." | ( Matsuda, M; Taguchi, H; Takaoka, K, 1992) |
| "Most of renal cell carcinomas (RCCs) are refractory at the start of chemotherapy." | ( Hashimura, T; Kakehi, Y; Segawa, T; Yoshida, O, 1992) |
| "Twenty four patients with advanced renal cell carcinoma were treated in a phase II trial with amonafide 300-450 mg/m2/day on days 1-5 every 21 days." | ( Craig, JB; Crawford, ED; Goodman, P; Higano, CS; Kish, JA; Rivkin, SE; Wolf, M, 1991) |
| "The authors treated 10 advanced renal cell carcinoma with circadian venous continuous infusion of 5-Fluoro 2-Deoxyuridine (FUDR)." | ( Buzzetti, V; Cogni, M; Del Nero, A; Longo, G; Mandressi, A; Mangiarotti, B; Russo, R, 1991) |
| "Fifteen patients with advanced renal cell carcinoma were treated with Menogaril, 200 mg/m2 by one-hour, intravenous infusion at four-week intervals." | ( Buckner, JC; Frytak, S; Hahn, RG; Hauge, MD; Long, HJ; Therneau, TM, 1991) |
| "Twenty-five patients with renal cell carcinoma were treated with a lipophilic macromolecular drug, poly(stylene-co-maleic acid)-conjugated neocarzinostatin (SMANCS) dissolved in lipid contrast medium (Lipiodol)." | ( Imai, K; Kobayashi, M; Konno, T; Maeda, H; Sugihara, S; Yamanaka, H, 1991) |
| "Current therapies for renal cell carcinoma have been limited by the unresponsiveness of metastatic disease to conventional treatments." | ( Bucana, CD; Dinney, CP; Fidler, IJ; Killion, JJ; Utsugi, T; von Eschenbach, AC, 1991) |
| "The authors treated 42 metastatic renal cell carcinoma (RCC) patients who had received no previous chemotherapy or radiation therapy with circadian venous continuous infusion of 5-fluoro-2-deoxyuridine (FUDR)." | ( Bonalumi, MG; Comeri, G; Damascelli, B; Del Nero, A; Garbagnati, F; Lutman, R; Marchianò, A; Mauri, M; Salvetti, M; Spreafico, C, 1990) |
| "Eighty patients of renal cell carcinoma were treated during the period." | ( Akimoto, M; Hara, M; Hasegawa, J; Kawamura, N, 1990) |
| "In a randomized study of advanced renal cell carcinoma 60 patients were allocated to treatment with either recombinant interferon alpha-2a or medroxyprogesterone acetate." | ( Achtnich, U; Arvidsson, A; Borgström, E; Carbin, BE; Esposti, PL; Näslund, I; Söderlund, V; Steineck, G; Strander, H; Wallin, L, 1990) |
| "Six patients with advanced renal cell carcinoma was treated with a new chemo-endocrine regimen consisting of Tegafur, Adriamycin, Methotrexate and Tamoxifen." | ( Abe, T; Aizawa, M; Morikawa, E; Takagi, H; Wada, A; Wada, T; Yasutomi, M, 1990) |
| "Tumor cells isolated from human renal cell carcinoma biopsies were treated with cholesteryl hemisuccinate or 25-hydroxycholesterol and the subsequent changes in their membrane fluidity and capacity to induce skin reactivity in the homologous patient were investigated." | ( Beck, JP; Bollack, C; Cremel, G; Hubert, P; Jacqmin, D; Ludes, B; Staedel, C, 1990) |
| "Sixty eight patients with renal cell carcinoma were treated at our University in 1968 approximately 1983." | ( Imai, K; Ito, Y; Kobayashi, M; Nagata, M; Nakai, K; Suzuki, T; Yamanaka, H, 1985) |
| "Eighteen patients with stages I to III renal cell carcinoma were treated with Neocarzinostatin before, during and after nephrectomy." | ( Negishi, T; Ohwada, F; Saitoh, T; Satake, I; Tari, K, 1989) |
| "Chemotherapy of metastatic renal cell carcinoma has a poor effect." | ( Chaitchik, S; Laufer, R; Merimsky, O, 1989) |
| "Twelve patients with metastatic renal cell carcinoma underwent pretreatment nephrectomy and these tumors were also studied." | ( Elwood, LJ; Lotze, MT; Rosenberg, SA; Rubin, JT, 1989) |
| "Fourteen patients with metastatic renal cell carcinoma (RCC) were treated with high-dose folinic acid (HDFA): 200 mg/m2 i." | ( Ferrari, V; Marini, G; Marpicati, P; Montini, E; Simoncini, E; Zaniboni, A, 1989) |
| "A case of renal cell carcinoma with multiple lung metastases successfully treated with interferon (IFN) following nephrectomy is reported." | ( Horie, M; Kawada, Y; Kobayashi, S; Komeda, H; Kuriyama, M; Takahashi, Y; Yamada, S, 1989) |
| "Metastatic renal cell cancer is one of the histological types of tumors particularly susceptible to this treatment approach although renal toxicity often is a dose-limiting side effect." | ( Austin, HA; Belldegrun, A; Linehan, WM; Rosenberg, SA; Steinberg, SM; Webb, DE, 1989) |
| "Eighteen patients with advanced renal cell cancer were evaluated for objective response to a combination chemotherapy regimen twenty-eight-day (d) cycles, with dacarbazine (200 mg/sq m/d, d1,2,3); cyclophosphamide (400 mg/sq m/d, d1); cisplatin (100 mg/sq m/d, d1); doxorubicin (50 mg/sq m/d, d1); vindesine (1." | ( Court, BH; Droz, JP; Ghosn, M; Lupera, H; Theodore, C; Wibault, P, 1989) |
| "NMF is not an active agent in renal cell cancer when administered by this schedule." | ( Abrams, JS; Aisner, J; Eisenberger, M; Olver, IN; Silva, H; Tait, N; Van Echo, DA, 1989) |
| "The response rates in metastatic renal cell cancer (RCC) after chemotherapy, hormonal treatment, or immunotherapy rarely exceed 15%." | ( Aulitzky, W; Gottwald, A; Hautmann, R; Messerer, D; Moormann, JG; Porzsolt, F; Rasche, H; Schumacher, K; Sparwasser, H; Stockamp, K, 1988) |
| "Our results indicate that metastatic renal cell cancer responds to infusional chemotherapy and that the circadian shape of infusion markedly affects our ability to deliver effective doses." | ( Fraley, EE; Hrushesky, WJ; Rabatin, JT; Von Roemeling, R, 1988) |
| "Fifteen patients with advanced renal cell carcinoma underwent chemotherapy of neocarzinostatin (NCS)." | ( Kojima, S; Satake, I; Tari, K; Tsujii, T; Yonese, J, 1988) |
| "A case of multiple lung metastasis of renal cell carcinoma in which complete remission was obtained with administration of UFT (Tegafur + Uracil) is reported." | ( Fukushima, S; Sakuramoto, T; Sugawara, T, 1987) |
| "A rare case of metastatic renal cell carcinoma which represented complete remission by chemotherapy and surgical treatment is presented." | ( Fukuoka, H; Goto, A; Kitamura, H; Murai, T, 1987) |
| "Thirty patients with metastatic renal cell cancer were treated by renal infarction, followed by delayed nephrectomy." | ( Crawford, ED; Gottesman, JE; Grossman, HB; McCracken, JD; Scardino, P, 1985) |
| "Sixteen patients with adult metastatic renal cell carcinoma were treated with elliptinium acetate, 80 mg/m2." | ( Amiel, JL; Droz, JP; Ghosn, M; Piot, G; Rouëssé, J; Theodore, C, 1988) |
| "After 1 year, primary renal cell carcinoma and metastases to liver, lung, and peritoneum were observed only in Fe-NTA-treated rats (14 of 18 surviving rats)." | ( Ebina, Y; Hamazaki, S; Li, JL; Midorikawa, O; Ogino, F; Okada, S, 1986) |
| "Nineteen patients with renal cell carcinoma who had undergone radical nephrectomy have been treated with a combination of chemotherapy and partly hormonal therapy using ACNU, vinblastine and chloromadinone acetate." | ( Imai, K; Ito, Y; Kobayashi, M; Kumasaka, F; Nakai, K; Sugihara, S; Suzuki, T; Yamanaka, H, 1986) |
| "Forty-five patients with metastatic renal cell carcinoma were treated with coumarin (1,2-benzopyrone) and cimetidine." | ( Butler, K; Cantrell, J; Macdonald, JS; Marshall, ME; Mendelsohn, L; Riley, L; Taylor, R; Wiseman, C, 1987) |
| "We report 3 cases of renal cell carcinoma in a solitary kidney treated by selective tumor embolization." | ( Barry, J; Keller, FS; Kozak, BE; Rosch, J, 1987) |
| "Twenty-three patients with advanced renal cell carcinoma (RCC) were treated with vinblastine at a dose of 0." | ( Cordon-Cardo, C; Fischer, P; Lianes, P; Lyn, P; Motzer, RJ; Ngo, RL; O'Brien, JP, 1995) |
| "Patients with disseminated renal cell carcinoma were treated with continuous infusion of 18 x 10(6) IU/m2/24 h for 4 days followed by 3 days without treatment, for 4 consecutive weeks." | ( Anderson, JA; Edwards, MJ; Harty, JI; Knott, AW; Woodcock, TM, 1995) |
| "A 60-year-old man with renal cell carcinoma and metastases to the right 7th rib and L2 vertebra (T2N0M1, OSS) was treated with interferon-alpha and the uracil and tegafur combination following nephrectomy." | ( Maehara, Y; Satoh, J; Shibata, Y; Shimizu, TS; Sugihara, S; Uchida, T, 1994) |
| "Fourteen patients with metastatic renal cell carcinoma and 10 with metastatic melanoma being treated in a phase 2 study of the sequential combination of interferon-gamma and interleukin-2." | ( Baars, JW; Eerenberg-Belmer, AJ; Hack, CE; Hart, MH; Pinedo, HM; Wagstaff, J; Wolbink, GJ, 1994) |
| "Advanced metastatic renal cell carcinoma has been shown to be responsive to immunotherapy but the response rate is still limited." | ( Ali, E; Haas, GP; Hillman, GG; Lam, JS; Montecillo, E; Pontes, JE; Puri, RK; Visscher, D; Younes, E, 1995) |
| "Fourteen patients with advanced renal cell carcinoma were treated on a phase II trial with liposomal encapsulated doxorubicin (Lipodox, LED)." | ( Law, TM; Mencel, P; Motzer, RJ, 1994) |
| "Fifteen patients with advanced renal cell carcinoma were treated on a phase II trial with topotecan." | ( Ilson, DH; Law, TM; Motzer, RJ, 1994) |
| "An orthotopic metastatic human renal cell carcinoma model in nude mice was established to evaluate the mechanism of metastasis as a preliminary phase in the development of a treatment to prevent cancer metastasis." | ( Gohji, K; Kamidono, S, 1994) |
| "The response rate of metastatic renal cell cancer to cytotoxic therapy over the last 10 years has been 5." | ( Bueschen, A; Crawford, ED; Flanigan, RC; Kish, JA; Leimert, JT; Neefe, JR; Wolf, M, 1994) |
| "The effect of treating a human renal cell adenocarcinoma xenografted into Balb/c-nu/nu (nude) mice with recombinant human tumor necrosis factor alpha (TNF alpha) and the cytostatic agent etoposide (ETP) as monotherapy or combination has been studied." | ( Bassukas, ID; Heimbach, D; Hofmockel, G; Maurer-Schultze, B; Wirth, M, 1993) |
| "In patients with progressive metastatic renal cell carcinoma, we established a three-drug combination comprising interferon-alpha (IFN-alpha), interleukin-2 (IL-2) and 5-fluorouracil (5-FU), using a regimen which allows outpatient therapy." | ( Atzpodien, J; Deckert, M; Fenner, M; Hänninen, EL; Kirchner, H; Poliwoda, H, 1993) |
| "The prognosis of metastatic renal cell cancer is unfavourable as neither chemo-, radiation- nor hormonal therapy achieve tumor remissions in more than 10% of the patients." | ( Sagaster, KP, 1993) |
| "Four patients with metastatic renal cell carcinomas were treated with intraarterial chemotherapy using vinblastine and/or adriamycin in combination with cepharanthine for their metastatic lesions (3 bone and 1 contralateral kidney metastases)." | ( Hashimura, T; Kakehi, Y; Kanematsu, A; Segawa, T; Yoshida, O, 1993) |
| "Cytokine treatment of renal cell carcinoma is described, focusing on interferons (IFN) and interleukin-2 (IL-2)." | ( Tazaki, H, 1994) |
| "One potential explanation for why renal cell carcinoma is usually poorly responsive to chemotherapy is intrinsic multidrug resistance." | ( Grosh, W; Loehrer, PJ; Murphy, BR; Pennington, KL; Rynard, SM, 1994) |
| "A high incidence of renal adenocarcinoma has been observed in rats treated with ferric nitrilotriacetate (Fe-NTA) but not in rats treated with aluminum nitrilotriacetate (Al-NTA)." | ( Deguchi, J; Kawabata, T; Kondo, A; Okada, S, 1993) |
| "Twenty-nine patients with metastatic renal cell carcinoma (RCC) were treated with constant-infusion floxuridine (FUdR, Roche Laboratories, Nutley, NJ)." | ( Carroll, PR; Ernest, ML; Frye, JW; Small, EJ; Stagg, RJ; Venook, AP; Wilkinson, MJ, 1993) |
| "Treatment of patients with metastatic renal cell carcinoma with high-dose interleukin-2 (IL-2) administered as continuous intravenous (CIV) infusion or as bolus injection results in response rates of 15% to 30%; however, toxicities with these regimens have been severe." | ( Shulman, KL; Stadler, WM; Vogelzang, NJ, 1996) |
| "Seventeen patients with metastatic renal cell carcinoma were treated with IL-2 by CIV at a dose of 18 x 10(6) IU/m2/day for 5 days followed by 4 to 6 days of rest followed by 10 days of CIV IL-2 at a dose of 6 x 10(6) IU/m2/day." | ( Shulman, KL; Stadler, WM; Vogelzang, NJ, 1996) |
| "We found eight patients with renal cell carcinoma who developed carpal tunnel syndrome (CTS) during treatment with IL-2, fluorouracil (5-FU), and alpha-interferon (alpha-IFN)." | ( Austin, SG; Forman, AD; Puduvalli, VK; Sella, A, 1996) |
| "Advanced renal cell carcinoma still has poor overall treatment results, whatever chemotherapy is used." | ( Jekunen, A; Pyrhönen, S, 1996) |
| "Three patients with lung metastases of renal cell carcinoma (RCC) were treated with a combination of interferon-alpha, leucovorin and 5-fluorouracil." | ( Demura, T; Hirakawa, K; Hirano, T; Ohashi, N; Sindoh, J; Tabata, T; Togashi, M, 1996) |
| "Human renal adenocarcinomas do not adequately respond to cancer chemotherapy." | ( Deguchi, T; Ehara, H; Kawada, Y; Kawamoto, S; Nezasa, S; Okano, M; Tamaki, M; Yamada, S, 1996) |
| "In human renal cell carcinoma (RCC), it has recently been reported that immunotherapy with interferon (IFN) is effective for the prevention of tumor recurrence and progression." | ( Imagawa, M; Mimata, H; Nakagawa, M; Nomura, Y; Ogata, J; Takahashi, S, 1996) |
| "Eleven patients with metastatic renal cell carcinoma received combination therapy with 5-fluorouracil (5-FU), Cisplatin (CDDP) and Interferon alpha-2b (IFN alpha-2b)." | ( Fujinami, K; Ikeda, I; Kondo, I; Miura, T, 1996) |
| "A 73-year-old man with renal cell carcinoma involving the left renal vein was treated with the embolization of the left renal artery followed by interferon-alpha and UFT." | ( Hamaguchi, K; Kamura, K; Matsushita, K; Seto, K; Shiomi, K; Yamauchi, T, 1997) |
| "Conventional therapy for renal cell carcinoma using interferon (IFN) has shown limited antitumor action." | ( Marumo, K; Murai, M; Oya, M, 1997) |
| "Metastatic renal cell carcinoma has a poor prognosis, requiring systemic therapy, in addition to radical nephrectomy." | ( Aveta, P; Cracco, C; Neira, D; Rocca Rossetti, S; Terrone, C, 1997) |
| "The protocol for renal cell carcinoma consisted of combined chemotherapy with continuous infusion of 5-FU 250 mg/m2/day and CDDP 3 mg/m2/day in 2 weeks for 1 cycles (4 weeks)." | ( Hata, M; Ono, S; Ota, N; Otsuka, A, 1997) |
| "In 89 patients with localized renal cell carcinoma treated with radical nephrectomy, long-term renal function, morbidity, and survival were evaluated." | ( Alamdari, FI; Duchek, M; Granfors, T; Holmberg, G; Ljungberg, B, 1998) |
| "Metastatic or recurrent renal cell carcinoma (RCC) is a therapeutic challenge because it is resistant to chemotherapy and external radiotherapy." | ( Armatis, P; Groot, K; Halmos, G; Jungwirth, A; Pinski, J; Schally, AV; Szepeshazi, K, 1998) |
| "Immunotherapy management for advanced renal carcinoma has awaken a growing interest over the last few years." | ( García Bueno, JM; Gutiérrez Sanz-Gadea, C; Hidalgo Pardo, F; Losada González, GP; Mus Malleu, A; Ozonas Moragues, M; Rebassa Llull, MJ, 1998) |
| "Eligible patients had advanced renal cell carcinoma with bi-dimensionally measurable disease, a Karnofsky performance status of at least 70, life expectancy of greater than three months, no evidence of brain metastases, and treatment with no more than one chemotherapy regimen." | ( Amsterdam, A; Berg, WJ; Law, TM; Mazumdar, M; Motzer, RJ; Nanus, DM; Schwartz, LH; Vlamis, V, 1997) |
| "Therapy of advanced renal cell carcinoma remains difficult." | ( Gross, AJ; Hemmerlein, B; Kallerhoff, M; Kugler, A; Ringert, RH; Seseke, F, 1998) |
| "Explants of highly metastatic human renal cell carcinoma SN12Cpm6 cells in athymic mice were treated with sodium D-glucaro-delta-lactam (sodium 5-amino-5-deoxy-D-glucosaccharic acid-delta-lactam; ND-2001)." | ( Hamada, J; Hosokawa, M; Kobayashi, H; Kuramitsu, Y; Morikawa, K; Naito, S; Tsuruoka, T, 1998) |
| "Metastatic renal carcinoma has a 2-year survival of around 20% and is largely resistant to chemotherapy." | ( , 1999) |
| "In patients with advanced metastatic renal cell carcinoma (RCC) seen at a single institution, the toxicity and long-term clinical effects of a combination therapy with recombinant interleukin-2 (rIL-2), recombinant interferon-alpha2 (rIFN-alpha2) and 5-fluorouracil (5-FU) were evaluated." | ( Allhoff, EP; Gruss, A; Reiher, F; Samland, D; Schmidt, U; Steinbach, F, 1999) |
| "Among 16 patients with renal cell carcinoma treated, four had major (clinical partial response) responses, one of which was demonstrated to be a pathologic clinical response after surgical resection of a residual mass." | ( Altobelli, KK; Binder, M; Clark, D; Elias, L; Mangalik, A; Morrison, B; Smith, A, 1999) |
| "To identify the outer border of a renal cell carcinoma (RCC) during a kidney-preserving tumour resection by photodynamically detecting RCC after the exogenous administration of 5-aminolaevulinic acid (ALA) in an animal model and in humans." | ( Popken, G; Schultze-Seemann, W; Wetterauer, U, 1999) |
| "Twenty metastatic renal cell cancer patients were treated with subcutaneous IL-2 immunotherapy (6 000 000 IU day(-1) for 6 days per week for 4 weeks); tumour response consisted of partial response (PR) in four patients, stable disease (SD) in eight patients and progressive disease (PD) in eight patients." | ( Di Felice, G; Fumagalli, L; Lissoni, P; Mengo, S; Meregalli, S; Rovelli, F; Valsuani, G, 1999) |
| "Patients with metastatic renal cell carcinoma receiving a 5-day continuous infusion of IL-2 (18 million IU/m2/d) who developed hypotension were treated with increasing doses of NMA, ranging from 3 to 36 mg/kg." | ( Fonseca, GA; Griffith, OW; Kilbourn, RG; Trissel, LA, 2000) |
| "In patients with metastatic renal cell carcinoma response rates of 7-26% have been achieved with immunotherapy." | ( De Mulder, PH; Groenewegen, G; Hoekman, K; Jansen, RL; Kruit, WH; Osanto, S; van Herpen, CM, 2000) |
| "Among 467 patients with renal cell carcinoma treated between April 1984 and March 1993, 191 were treated with SMANCS dissolved in a lipid contrast medium (a 3:2 mixture of Lipiodol F and Lipiodol Ultrafluid; Lpd)." | ( Kobayashi, M; Konno, T; Maeda, H; Tsuchiya, K; Uchida, T; Yamanaka, H, 2000) |
| "Treatment of metastatic renal cell carcinoma (RCC) remains unsatisfactory." | ( Bukowski, RM, 2000) |
| "Metastatic renal cell carcinoma remains one of the most treatment-resistant malignancies in humans." | ( Berg, WJ; Divgi, CR; Motzer, RJ; Nanus, DM, 2000) |
| "Treatment of patients with metastatic renal cell cancer (RCC) with interferon-alpha-2a (IFN) and 13-cis-retinoic acid (CRA) was first reported to be tolerable on an outpatient basis and to yield a 30% objective response rate." | ( Aboulafia, D; Gold, P; Jacobs, A; Picozzi, V; Rudolph, R; Thompson, J; Weiden, P, 2000) |
| "Patients with metastatic renal cell carcinoma have a poor prognosis and no standard therapy is available." | ( Amato, R; Daliani, D; Jones, D; Logothetis, C; Millikan, R; Pagliaro, L; Smith, T; Tu, SM, 2000) |
| "55 patients with advanced renal cell cancer were treated as follows: IL-2 and IFN-alpha according to the schedule originally described by Atzpodien, with PVI 5FU 200 mg m(-2)day(-1)during weeks 5-9." | ( Ahern, R; Allen, MJ; Bate, S; Eisen, T; Gore, ME; Johnston, S; Moore, J; Savage, P; Vaughan, M; Webb, A, 2000) |
| "Patients with renal cell carcinoma rarely suffer from anemia and thus are usually not candidates for EPO treatment." | ( Albers, P; Heicappell, R; Schwaibold, H; Wolff, J, 2001) |
| "Twenty-nine patients with advanced renal carcinoma and eleven patients with lymphoma were treated with poly ICLC." | ( Blum, R; Giantonio, BJ; Hochster, H; Hudes, GR; Kirkwood, J; Oken, MM; Trump, D; Wiernik, PH, 2001) |
| "Six patients with renal carcinoma had stable disease as best response with one patient receiving 62 weeks of therapy." | ( Blum, R; Giantonio, BJ; Hochster, H; Hudes, GR; Kirkwood, J; Oken, MM; Trump, D; Wiernik, PH, 2001) |
| "Chemotherapy resistance of renal cell carcinoma (RCC) has been attributed in large part to multidrug resistance (MDR)." | ( Chang, YH; Chen, KK; Chen, PM; Fan, FS; Liu, JH; Wang, WS; Yang, MH; Yen, CC, 2001) |
| "A 52-year-old man with renal cell carcinoma was treated with surgery and chemotherapy (vinblastine)." | ( Prokopchuk, OL; Susak, YM; Zemskov, SV, 2000) |
| "We have treated Caki-2 human renal cell carcinoma in vivo using herpes simplex virus thymidine kinase (HSV-tk) gene therapy." | ( Ala-Opas, MY; Kauppinen, RA; Kettunen, MI; Laukkanen, JM; Parkkinen, JJ; Pulkkanen, KJ; Tyynela, K; Yla-Herttuala, S, 2001) |
| "Thirty patients with advanced renal cell carcinoma were treated on a phase 11 trial with altretamine." | ( Ansari, R; Helman, D; Loehrer, PJ; McClean, J; Picus, J; Sandler, A; Williams, SD; Zon, RT, 2001) |
| "Eligible patients had advanced renal cell carcinoma with bidimensionally measurable disease, a Karnofsky performance status of at least 70, life expectancy of greater than three months, no prior treatment with chemotherapy, and no evidence of brain metastases." | ( Berg, WJ; Mazumdar, M; Motzer, RJ; Schwartz, L; Yu, R, 2001) |
| "The murine renal carcinoma (Renca) pulmonary metastases model was used to determine the therapeutic effect of drug formulation administered by aerosol." | ( Golunski, E; Knight, V; Koshkina, NV; Melton, S; Roberts, LE; Waldrep, JC, 2001) |
| "Twenty-eight patients with metastatic renal cell carcinoma were treated with high-dose intravenous, low-dose intravenous, or subcutaneous IL-2 therapy." | ( Cecco, SA; Cormier, J; Elin, RJ; Kim, CJ; McKee, MD; Niemela, JE; Rehak, NN; Rosenberg, SA; Steinberg, SM, 2002) |
| "Twelve patients with refractory renal cell cancer were treated on a phase II study of pegylated-liposomal doxorubicin (Doxil)." | ( Skubitz, KM, 2002) |
| "The treatment of metastatic renal cell cancer remains unsatisfactory despite encouraging results with biotherapy." | ( Church, CK; DePriest, CB; Dillman, RO; Schulof, R; Soori, G; Stark, JJ; Tai, F; Wiemann, MC, 2002) |
| "Eligible patients had metastatic renal cell cancer, were in good medical condition, and had not been treated previously with more than two of the study agents." | ( Church, CK; DePriest, CB; Dillman, RO; Schulof, R; Soori, G; Stark, JJ; Tai, F; Wiemann, MC, 2002) |
| "Since metastatic renal cell carcinoma has a poor prognosis and treatment strategies, including hormone therapy, chemotherapy and immunotherapy, have little impact on the quality of life and global survival statistics, new interest has recently focused on the combination of immuno-chemotherapy using pyrimidine analogues, such as gemcitabine." | ( Cini, G; Di Cello, V; Dominici, A; Doni, L; Fulignati, C; Gemelli, MT; Maleci, M; Mottola, A; Neri, B; Ponchietti, R; Raugei, A; Turrini, M; Valsuani, G, 2002) |
| "Fourteen patients with metastatic renal cell carcinoma (RCC) were treated on a Phase II trial with arsenic trioxide (As2O3)." | ( Motzer, RJ; Schwartz, L; Vuky, J; Yu, R, 2002) |
| "Although human renal cell carcinoma (RCC) is considered refractive to hormone therapy, this lesion can be induced in the Syrian hamster by exogenous estrogen." | ( Chawla, S; Dorn, S; Imperato, PJ; Mydlo, JH; Shah, S; Volpe, MA, 2002) |
| "An 83-year-old man with left renal cell carcinoma (RCC; pT4N0M0) was treated with postoperative combined subcutaneous injection therapy of alpha interferon (IFN-alpha) and IFN gamma-1a (IFN-gamma-1a)." | ( Okabe, T; Yoshino, S, 2003) |
| "Thus, clinical experience with renal cell carcinoma in this age group is meager and no consensus between pediatric urologists and pediatric oncologists exists on common treatment strategies." | ( Ebert, A; Gravou, C; Rösch, WH; Stümpfl, M, 2003) |
| "Patients with disseminated renal cell carcinoma (RCC) have a poor outcome, and the disease is considered highly resistant to chemotherapy." | ( Chevreau, C; Culine, S; Droz, JP; Escudier, B; Fizazi, K; Mery-Mignard, D; Rolland, F, 2003) |
| "The median survival of metastatic renal cell carcinoma (RCC) is 12 months, and the majority of treatment options are palliative." | ( Brannon, J; Dent, P; Fisher, PB; Gopalkrishnan, RV; Grant, S; Lebedeva, IV; Linehan, WM; McKinstry, R; Mitchell, C; Qiao, L; Rosenberg, E; Sarkar, D; Su, ZS; Valerie, K; Yacoub, A, 2003) |
| "Eighteen patients with advanced renal cell carcinoma (RCC) were treated on a phase II trial with ZD1839 (IRESSA)." | ( Bacik, J; Drucker, B; Ginsberg, M; Marion, S; Mazumdar, M; Motzer, R; Russo, P, 2003) |
| "Metastatic renal cell carcinoma (RCC) is rising in incidence but remains difficult to treat." | ( Blatter, J; Hanauske, A; Ohnmacht, U; Sauter, T; Thödtmann, R; Weinknecht, S; Weissbach, L, 2003) |
| "Four patients with metastatic renal cell carcinoma and high serum levels of CRP and IL-6 who had experienced disease progression on IL-2 were retreated with the same IL-2 regimen combined with thalidomide 300 mg p." | ( Ivgi, H; Kedar, I; Mermershtain, W, 2004) |
| "Patients with metastatic clear cell renal cell carcinoma and no prior systemic therapy were accrued." | ( Brinkley, W; Clark, PE; Das, S; Hall, MC; Lovato, JF; Miller, A; Patton, SE; Ridenhour, KP; Stindt, D; Torti, FM, 2004) |
| "Advanced renal cell carcinoma (RCC) is resistant to cytotoxic chemotherapy, and immunotherapy has modest activity." | ( An, J; Fisher, M; Rettig, MB; Sun, Y, 2004) |
| "In patients with metastatic renal cell carcinoma (MRCC), interferon-alpha (IFN) monotherapy leads to response rates of 5-15%, dependent on the selection of patients." | ( Croles, JJ; De Mulder, PH; de Prijck, L; Fey, M; Fosså, SD; Horenblas, S; Mickisch, GH; Van Glabbeke, M; van Oosterom, AT; van Poppel, H, 2004) |
| "However the gene expression profile in renal cell carcinoma (RCC) in response to RE treatment has never been reported." | ( Almasan, A; DiDonato, JA; Duan, ZH; Hissong, JG; Liou, LS; Novick, AC; Sadhukhan, P; Shi, T, 2004) |
| "Metastatic renal cell carcinomas (RCC) remain highly resistant to systemic therapy." | ( Fujii, Y; Iwai, A; Kageyama, Y; Kawakami, S; Kihara, K; Takazawa, R; Yoshida, MA, 2004) |
| "Conventional therapy for renal cell carcinoma (RCC) using interferon (IFN) has shown limited antitumor action." | ( Ishii, T; Marumo, K, 2004) |
| "Thirty-one patients with metastatic renal cell carcinoma were treated with intratumorally administered Leuvectin at doses ranging from 0." | ( Akporiaye, ET; Burch, PA; Frytak, S; Galanis, E; Kaur, JS; Lewis, B; Okuno, SH; Peethambaram, PP; Pitot, HC; Richardson, RL; Rubin, J; Spier, C; Unni, KK, 2004) |
| "Treatment of metastatic renal cell carcinoma with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning with fludarabine/total body irradiation is feasible and may induce tumor regression or stabilization in some patients." | ( Childs, RW; Leppert, MF; Otterud, BE; Riddell, SR; Sandmaier, BM; Storb, R; Thompson, JA; Tykodi, SS; Warren, EH, 2004) |
| "Metastatic renal cell carcinoma (RCC) has modest response rates to chemotherapy with gemcitabine and 5-fluorouracil (5-FU)." | ( Rini, BI; Small, EJ; Weinberg, V, 2005) |
| "Human renal carcinoma cells (RCCs) were sensitized to the apoptotic effects of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), by treatment with cycloheximide (CHX)." | ( Brooks, AD; Sayers, TJ, 2005) |
| "Metastatic renal cell carcinoma, inherently resistant to conventional treatments, is considered immunogenic." | ( Caignard, A; Chouaib, S; Da Rocha, S; Escudier, B; Fromont, G; Morel, Y; Viey, E, 2005) |
| "Transcriptional patterns in PBMCs of 45 renal cell cancer patients were compared with clinical outcome data at the conclusion of a phase II study of the mTOR kinase inhibitor CCI-779 to determine whether pretreatment transcriptional patterns in PBMCs were correlated with eventual patient outcomes." | ( Burczynski, ME; Dorner, AJ; Dukart, G; Dutcher, J; Hidalgo, M; Hudes, G; Immermann, F; Logan, T; Marshall, B; Slonim, DK; Stadler, WM; Strahs, A; Trepicchio, WL; Twine, NC, 2005) |
| "Treatment of renal cell carcinoma (RCC) is limited by its resistance to conventional chemotherapies." | ( Davidson, K; Gobe, GC; Johnson, DW; Li, J; Nicol, D; Pat, BK; Percy, C; Rennick, AJ, 2005) |
| "Two patients with advanced renal cell carcinoma underwent allogeneic hematopoietic stem cell transplantation and received cyclosporine (CSP) as part of their immunosuppressive therapy." | ( Arahata, M; Asakura, H; Hayashi, T; Nakao, S; Namiki, M; Orito, M; Shibayama, M; Takamatsu, H; Takami, A; Yamazaki, H; Yoshida, T, 2005) |
| "Therapy for advanced renal cell carcinoma (RCC) is ineffective in the majority of patients." | ( Goldberg, JS; Gudas, LJ; Guo, X; Moench, P; Nanus, DM; Tickoo, SK; Touma, SE, 2005) |
| "Fourteen patients with metastatic renal cell carcinoma (RCC) were treated on a Phase II trial with imatinib." | ( Aboulafia, D; dela Cruz, J; Fotoohi, M; Isacson, C; Jacobs, A; Malpass, T; Otero, H; Picozzi, V; Vuky, J, 2006) |
| "The standard treatment for renal cell carcinoma (RCC) is surgery." | ( Kanetake, H; Koga, S, 2006) |
| "Seven male patients with metastatic renal cell carcinoma received intravenously administered busulfan at 3." | ( Alexander, W; Bachier, C; LeMaistre, C; Pollack, M; Ririe, D; Shaughnessy, P; Splichal, J; Tran, H, 2006) |
| "The treatment of advanced renal cell cancer remains unsatisfactory, therefore new combination regimens such as thalidomide and IL-2 are of interest." | ( Bukowski, RM; Dreicer, R; Elson, P; Malhi, S; Mekhail, T; Olencki, T; Wood, L, 2006) |
| "Metastatic renal cell carcinoma does not respond favorably to conventional treatment strategies and is not very responsive to cytokine therapy." | ( Bukowski, RM; Reddy, GK, 2006) |
| "Ten patients suffering from renal cell carcinoma were treated by RFA." | ( Anastasiadis, A; Boss, A; Clasen, S; Claussen, CD; Fenchel, M; Martirosian, P; Pereira, PL; Schick, F; Schraml, C, 2006) |
| "Treatment of human ACHN renal cell carcinoma (RCC) and A375 melanoma cells with the DNA demethylating nucleoside analog 5-AZA-2'-deoxycytidine (5-AZA-dC) synergistically augmented antiproliferative effects of IFN- alpha (alpha) 2 and IFN-beta (beta)." | ( Bae, SI; Beaulieu, N; Borden, EC; Cherkassky, L; Leaman, DW; Lindner, D; MacLeod, AR; Reu, FJ, 2006) |
| "Metastatic renal cell carcinoma (RCC) is currently one of the most treatment-resistant malignancies." | ( Eto, M; Naito, S, 2006) |
| "Treatment of the VHL-deficient human renal cell carcinoma cell line UMRC2 with the hydroxamic HDAC inhibitor LAQ824 resulted in a dose-dependent inhibition of HIF-1 alpha protein via a VHL-independent mechanism and reduction of HIF-1 alpha transcriptional activity." | ( Atadja, P; Carducci, MA; Collis, SJ; Kachhap, SK; Pili, R; Qian, DZ; Verheul, HM, 2006) |
| "All tumors were confirmed to be renal cell carcinoma before radio frequency ablation treatment." | ( Anfossi, E; Bastide, C; Garcia, S; Ragni, E; Rossi, D, 2006) |
| "A 65-year-old man with metastatic renal cell carcinoma developed progressive disease after treatment with interferon-alpha." | ( Ginsberg, MS; Kondagunta, GV; Motzer, RJ; Ronnen, EA; Russo, P, 2006) |
| "Eighteen patients with metastatic renal cell carcinoma were treated with ATRA followed by s." | ( Antonia, S; Dunn, M; Fishman, M; Fricke, I; Frost, TJ; Gabrilovich, DI; Lush, RM; Mirza, N; Neuger, AM, 2006) |
| "Seventy-three patients with metastatic renal cell carcinoma were treated with sunitinib at the Cleveland Clinic Taussig Cancer Center, and 66 of them had thyroid function test results available." | ( Bukowski, RM; Dreicer, R; Garcia, J; Reddy, S; Rini, BI; Salas, R; Shaheen, P; Tamaskar, I; Wood, L, 2007) |
| "Metastatic renal cell carcinoma has long been recognized as an aggressive, therapy-refractory epithelial cancer." | ( Dreicer, R, 2006) |
| "The treatment of metastatic renal cell carcinoma (RCC) remains a clinical challenge." | ( Alamdari, FI; Grankvist, K; Ljungberg, B; Rasmuson, T, 2007) |
| "Nephron-sparing surgery for renal cell carcinoma involving a solitary kidney provides effective curative treatment for small tumours, with preservation of renal function." | ( Berdjis, N; Hakenberg, OW; Manseck, A; Novotny, V; Oehlschläger, S; Wirth, MP, 2007) |
| "Due to the chemoresistance of renal cell cancer, cytokine-based therapeutic approaches were considered the standard treatment for patients with metastatic disease." | ( Kruck, S; Kuczyk, M; Merseburger, AS, 2007) |
| "Since the histology of collecting duct carcinoma is similar to that of urothelial carcinoma, the standard chemotherapy regimen defined by a gemcitabine and platinum salts combination was prospectively investigated in patients with metastatic collecting duct carcinoma." | ( Arakelyan, N; Banu, A; Banu, E; Culine, S; Duclos, B; Escudier, B; Fournier, L; Medioni, J; Oudard, S; Priou, F; Rolland, F; Vieillefond, A, 2007) |
| "A total of 23 patients with metastatic collecting duct carcinoma with no prior systemic chemotherapy were treated with 1,250 mg/m(2) gemcitabine on days 1 and 8 plus 70 mg/m(2) cisplatin or carboplatin (AUC 5) in patients with renal insufficiency on day 1." | ( Arakelyan, N; Banu, A; Banu, E; Culine, S; Duclos, B; Escudier, B; Fournier, L; Medioni, J; Oudard, S; Priou, F; Rolland, F; Vieillefond, A, 2007) |
| "Treatment of the ACHN human renal cell carcinoma cell line with HGS-ETR1 combined with 5-fluorouracil, vinblastine or gemcitabine did not overcome resistance to these agents." | ( Abdel-Muneem Nouh, MA; Jin, X; Kakehi, Y; Wu, XX, 2007) |
| "The conversion of weakly apoptogenic renal cell carcinoma (RCC) clones to lines that can induce T cell death requires 3-5 days of TNF-alpha pretreatment, a time frame paralleling that needed for TNF-alpha to stimulate GM2 accumulation by SK-RC-45, SK-RC-54, and SK-RC-13." | ( Biswas, K; Biswas, S; Bukowski, R; Das, T; Finke, J; Ghosh, S; Hilston, C; Raval, G; Rayman, P; Sa, G; Tannenbaum, CS; Thornton, M, 2007) |
| "Approved for the treatment of advanced renal cell carcinoma by the US FDA and other regulatory agencies, sorafenib is an agent with multiple targets that may also prove beneficial in other malignancies." | ( Flaherty, KT, 2007) |
| "Metastatic renal carcinoma patients without prior fluoropyrimidine therapy and normal organ function were treated with oral capecitabine 880 mg/m(2) twice daily along with continuous infusion GTI-2040 starting at 148 mg/m(2)/day for 21 days, for each 28-day cycle." | ( Bukowski, R; Desai, AA; Kardinal, CG; Lewis, N; Makalinao, A; Murray, P; Poiesz, B; Quinn, DI; Stadler, WM; Torti, FM, 2008) |
| "An involvement of Pak1 in renal cell carcinoma (RCC), which remains highly refractory to chemotherapy and radiotherapy, remains to be investigated." | ( Ambrose, M; Barry, OP; Casey, G; Houston, A; O'Sullivan, GC; Tangney, M, 2007) |
| "Two patients with renal carcinoma underwent [11C]vinblastine PET before chemotherapy." | ( Bares, R; Blocher, A; Dohmen, BM; Machulla, HJ; Patt, M; Reimold, M; Solbach, C; Zeller, KP, 2007) |
| "Treatment of the ACHN human renal cell carcinoma (RCC) cell line with agonistic TRAIL-R2 antibody (lexatumumab) in combination with 5-fluorouracil, vinblastine, paclitaxel, or docetaxel did not overcome resistance to these agents." | ( El Hamed, AM; Jin, XH; Kakehi, Y; Wu, XX; Zeng, Y, 2007) |
| "Diagnosis of renal cell carcinoma (RCC) frequently occurs at advanced stages, severely limiting the success of treatment, and median survival is barely more than a year." | ( Manchen, B; Wood, LS, 2007) |
| "Patients with advanced renal cell carcinoma currently being treated with either sunitinib or sorafenib after receiving 1 or more prior antiangiogenic agent(s) were investigated in a retrospective analysis." | ( Bukowski, RM; Dreicer, R; Elson, P; Garcia, JA; Mekhail, T; Rini, BI; Tamaskar, I; Wood, L, 2008) |
| "Fourteen patients with metastatic renal cell carcinoma (RCC) were enrolled on a phase 2 trial of lenalidomide administered orally at 25 mg daily for 21 days followed by a rest period of 7 days." | ( Bacik, J; DeLuca, J; Ishill, N; Kondagunta, GV; Motzer, RJ; Patel, PH; Russo, P; Schwartz, L, 2008) |
| "Patients with advanced renal cell carcinoma and a poor prognosis who received a once-weekly intravenous infusion of temsirolimus 25 mg experienced significant survival benefits compared with patients receiving standard interferon-alpha (IFNalpha) therapy (3-18 MU subcutaneously three times weekly) in a large phase III clinical study." | ( Curran, MP; Simpson, D, 2008) |
| "Treatment of patients with metastatic renal cell carcinoma is evolving rapidly due to the advent of novel targeted therapies." | ( de Mulder, PH; Gietema, JA; Groenewegen, G; Haanen, JB; Jansen, RL; Kruit, WH; Mulders, PF; Osanto, S; Richel, DJ; Sleijfer, S; van den Eertwegh, AJ; Voest, EE, 2008) |
| "Treatments for metastatic renal cell carcinoma (MRCC) are limited." | ( Amato, RJ; Hernandez-McClain, J; Jac, J, 2008) |
| "In the pivotal phase III metastatic renal cell carcinoma trial, updated data indicates that 21% of sunitinib-treated patients experienced a decline in left ventricular ejection fraction to below normal." | ( Fisher, GA; Srinivas, S; Telli, ML; Witteles, RM, 2008) |
| "We present the case of a patient with renal cell carcinoma hospitalized for intractable cough that failed to respond adequately to usual treatments, but improved with diazepam." | ( Estfan, B; Walsh, D, 2008) |
| "The treatment of metastatic renal cell carcinoma (RCC) with high-dose interleukin-2 (HD IL-2) has resulted in durable tumor regression in a minority of patients." | ( Downey, SG; Hughes, MS; Kammula, US; Klapper, JA; Rosenberg, S; Royal, RE; Sherry, RM; Smith, FO; Steinberg, SM; Yang, JC, 2008) |
| "We report a renal cell carcinoma case in which multiple lung and bone metastases displayed remarkable remission to BP therapy using 30 mg pamidronate once, 4 mg zoledronate once, and weekly 10 mg incadronate 10 times for 3 months." | ( Fujii, Y; Fukui, I; Kijima, T; Okubo, Y; Suyama, T; Yonese, J, 2008) |
| "Treatments for refractory metastatic renal cell cancer (RCC) are limited." | ( Amato, RJ; Hernandez-McClain, J; Khan, M; Saxena, S, 2008) |
| "Patients with metastatic renal cell carcinoma (RCC) are often treated with cytokine therapy, although the effect is modest and second-line therapy is often warranted." | ( Bushmakin, AG; Bycott, P; Cappelleri, JC; Kim, S; Liau, K; Trask, PC, 2008) |
| "A 71-year-old man with advanced left renal cell carcinoma (lymph node involvement and vena cava thrombus) was submitted to 6 months of neoadjuvant treatment with sorafenib before open radical nephrectomy." | ( Andrea, A; Di Silverio, F; Panebianco, V; Parente, U; Passariello, R; Sciarra, A; Von Heland, M, 2008) |
| "Patients with metastatic clear cell renal cell carcinoma with available baseline tumor samples who received vascular endothelial growth factor targeted therapy were included in analysis." | ( Bhalla, IP; Bukowski, RM; Choueiri, TK; Elson, P; Ganapathi, R; Golshayan, AR; Jaeger, E; Rini, BI; Sein, N; Sercia, L; Simko, J; Small, EJ; Vaziri, SA; Waldman, FM; Weinberg, V; Wood, L; Zhou, M, 2008) |
| "Eighty-five patients with renal cell cancer treated between November 1, 2003, and February 28, 2005." | ( Autier, J; Escudier, B; Robert, C; Spatz, A; Wechsler, J, 2008) |
| "We describe a 75-year-old woman with renal cell carcinoma who was admitted to the intensive care unit after experiencing fulminant hepatic failure during sunitinib therapy." | ( Mueller, EW; Rashkin, MC; Rockey, ML, 2008) |
| "A better understanding of renal cell carcinoma biology has led to a new era of targeted therapy in the management of metastatic renal cell carcinoma." | ( Rini, BI; Vakkalanka, BK, 2008) |
| "In 10 patients with metastatic renal cell carcinoma treated with PTK787/ZK 222584, tumor blood flow was evaluated by arterial spin labeling (ASL) magnetic resonance imaging before and 1 month on treatment." | ( Alsop, DC; de Bazelaire, C; George, D; Michaelson, MD; Pedrosa, I; Rofsky, NM; Wang, Y, 2008) |
| "We report three cases of metastatic renal cell carcinoma (RCC) in which combination treatment of cimetidine, cyclooxygenase-2 inhibitor and renin-angiotensin system inhibitor (angiotensin converting enzyme inhibitor or angiotensin II type 1 receptor antagonist) (CCA therapy) was effective." | ( Fujii, Y; Fukui, I; Fukui, N; Kawakami, S; Kihara, K; Koga, F; Komai, Y; Morimoto, S; Saito, K; Tatokoro, M, 2008) |
| "Although medical treatment for advanced renal cell carcinoma has included cytokine therapies such as interferon and interleukin-2, the treatment system has been revolutionized with the emergence of molecular target medicine." | ( Fujioka, T; Obara, W, 2008) |
| "Treatment of advanced renal cell carcinoma (RCC) has undergone significant changes over the past 3 years after a long period of relative stagnation." | ( Bukowski, RM; Vakkalanka, BK, 2008) |
| "We treated 32 patients with advanced renal cell carcinoma with temsirolimus within the German compassionate use program on an individual patient basis free of charge according to EU guidelines at our two institutions." | ( Bergmann, L; Eimer, C; Gerullis, H; Maute, L; Otto, T, 2009) |
| "Therapy with temsirolimus in advanced renal cell carcinoma is well tolerated." | ( Bergmann, L; Eimer, C; Gerullis, H; Maute, L; Otto, T, 2009) |
| "Since the majority of clear cell renal cell carcinomas are well vascularised, angiogenetic inhibition offered an alternative therapy goal." | ( Haseke, N; Karl, A; Stadler, T; Staehler, M; Stief, CG; Zilinberg, K, 2008) |
| "Among patients with advanced renal cell carcinoma receiving sorafenib treatment, outcomes of older (>or=70 years) and younger (<70 years) patients were similar." | ( Anderson, S; Bukowski, R; Cihon, F; Eisen, T; Escudier, B; Gravis, G; Heinzer, H; Middleton, R; Oudard, S; Shah, S; Szczylik, C, 2008) |
| "Patients with renal cell carcinomas (RCC) have few treatment options, underscoring the importance of developing new approaches such as immunotherapy." | ( Arbour, N; Gunaratnam, L; Lapointe, R; Lee, S; Pelletier, S; Tanguay, S, 2009) |
| "Metastatic renal cell carcinoma (mRCC) with sarcomatoid differentiation is an aggressive disease that is associated with poor outcomes to chemotherapy or immunotherapy." | ( Aydin, H; Bukowski, RM; Elson, P; Garcia, JA; George, S; Golshayan, AR; Heng, DY; Mekhail, TM; Rini, BI; Wood, LS; Zhou, M, 2009) |
| "Treatment strategies for metastatic renal cell carcinoma (RCC) have been limited due to chemotherapy and radiotherapy resistance." | ( Blaheta, RA; Hintereder, G; Hudak, L; Jonas, D; Jones, J; Juengel, E; Mickuckyte, A; Wedel, S, 2009) |
| "A total of 19 patients with advanced renal cell carcinoma deemed unsuitable for initial nephrectomy due to locally advanced disease or extensive metastatic burden were treated with 50 mg sunitinib daily for 4 weeks on followed by 2 weeks off." | ( Campbell, SC; Dreicer, R; Garcia, J; Klein, EA; Lane, BR; Novick, AC; Rini, BI; Thomas, AA, 2009) |
| "Patients with metastatic renal cell carcinoma (RCC) generally show a poor prognosis; treatment approaches have not significantly improved patient survival." | ( Eimer, C; Gerullis, H; Otto, T, 2008) |
| "A Fuhrman III renal cell carcinoma was histologically confirmed on percutaneous biopsy, and sunitinib treatment was administered over 6 mo." | ( Ballanger, P; Bernhard, JC; Bram, R; Cornelis, F; Deminière, C; Gabbay, G; Ravaud, A; Robert, G; Wallerand, H, 2009) |
| "To report on 2 cases of metastatic renal cell cancer treated with sunitinib during chronic hemodialysis." | ( Froehner, M; Novotny, V; Platzek, I; Wirth, MP; Zastrow, S, 2009) |
| "Treatment of patients with advanced renal cell carcinoma (RCC) has changed dramatically with the advent of targeted therapeutics." | ( Bhatia, S; Thompson, JA, 2009) |
| "Treatment for metastatic renal cell cancer (mRCC) has advanced dramatically with understanding of the pathogenesis of the disease." | ( Mills, EJ; O'Regan, C; Perri, D; Rachlis, B; Thabane, L, 2009) |
| "The treatment options for metastatic renal cell carcinoma have expanded rapidly over the past 3 years, with four new agents available and others in late-stage development." | ( Porta, C; Szczylik, C, 2009) |
| "Treatment of ACHN human renal cell carcinoma cells with cisplatin combined with mapatumumab did not overcome resistance to these agents." | ( Kakehi, Y; Wu, XX, 2009) |
| "Advanced renal cell carcinoma (RCC) is resistant to chemotherapy and radiotherapy." | ( Mizutani, Y, 2009) |
| "The treatment of metastatic renal cell carcinoma (mRCC) has been changed by the introduction of targeted agents." | ( Bellmunt, J; Flodgren, P; Oudard, S; Roigas, J, 2009) |
| "Treatment options for metastatic renal cell carcinoma (RCC) are limited due to resistance to chemo- and radiotherapy." | ( Blaheta, RA; Engler, J; Hudak, L; Jonas, D; Jones, J; Juengel, E; Mickuckyte, A; Natsheh, I, 2009) |
| "Metastatic renal cell carcinoma (RCC) has traditionally been associated with a poor prognosis with few effective treatments." | ( Abel, EJ; Wood, CG, 2009) |
| "Metastatic renal cell carcinoma is notoriously resistant to chemotherapy and radiotherapy." | ( Abe, H; Fukabori, Y; Furuya, N; Kamai, T; Tokui, N; Yoshida, K, 2009) |
| "For many years, therapy for metastatic renal cell carcinoma (mRCC) was limited to a single line of cytokine therapy with either interferon or interleukin-2." | ( Melichar, B, 2009) |
| "Two patients with extensive bilateral renal cell carcinoma were also treated to downsize the tumors to enable partial nephrectomy." | ( Campbell, SC; Fergany, A; Garcia, JA; Gill, IS; Klein, EA; Krishnamurthi, V; Novick, AC; Rini, BI; Stephenson, AJ; Thomas, AA; Zhou, M, 2009) |
| "Surgical resection of renal cell carcinoma after targeted therapy is feasible with low morbidity in most patients." | ( Campbell, SC; Fergany, A; Garcia, JA; Gill, IS; Klein, EA; Krishnamurthi, V; Novick, AC; Rini, BI; Stephenson, AJ; Thomas, AA; Zhou, M, 2009) |
| "Patients with metastasized renal cell cancer after nephrectomy and progress after IL-2 and interferon treatment, received oral 5-FU at a dose of 1250 mg/qm(2) twice a day for two weeks, then after pausing a week, the oral application was restarted." | ( Brossart, P; Gorschlüter, M; Hauser, S; Kim, Y; Kraemer, A; Müller, SC; Schmidt-Wolf, IG, 2009) |
| "Patients with advanced papillary renal cell cancer (pRCC) have poor survival after systemic therapy; the reported median survival time is 7 to 17 months." | ( Clark, JI; Crawford, D; Dutcher, J; Gordon, MS; Hussey, M; Lara, PN; Mack, PC; Nagle, RB; Pan, CX; Quinn, DI; Samlowski, W, 2009) |
| "In metastatic renal cell carcinoma (mRCC), antiangiogenic treatments rarely achieve a reduction of -30% in the sum of longest diameters (SLD) of target lesions required by RECIST for an 'objective response', although they objectively improve progression-free survival (PFS)." | ( Balvay, D; Chatellier, G; Cuenod, CA; Dromain, C; Escudier, B; Fournier, LS; Medioni, J; Oudard, S; Thiam, R; Trinquart, L, 2010) |
| "We are presenting a case of renal cell carcinoma with multiple brain metastases that was successfully treated with multimodal therapy including a new type of medication." | ( Johnston, KW; Walid, MS, 2009) |
| "p53 mutations are rarely detected in clear cell renal cell carcinoma (CCRCC), but, paradoxically, these tumors remain highly resistant to chemotherapy and death receptor-induced death." | ( Evans, AJ; Foster, DA; Irwin, MS; Ohh, M; Roberts, AM; Watson, IR, 2009) |
| "In the treatment of advanced renal cell carcinoma, temsirolimus is administered as a 30- to 60-minute IV infusion once weekly at a flat dose of 25 mg." | ( Boni, JP; Hug, B; Leister, C; Sonnichsen, D, 2009) |
| "Metastatic renal cell carcinoma (mRCC) patients treated with anti-vascular endothelial growth factor (VEGF) therapies demonstrate promising outcomes but not all patients benefit." | ( Jonasch, E; Liu, W; Mills, GB; Petillo, D; Tamboli, P; Tannir, N; Teh, B; Tsavachidou-Fenner, D, 2010) |
| "Lung-metastasized renal cell carcinoma mice were treated with various combinations of recombinant human interleukin-2 and sorafenib." | ( Abe, K; Amagai, Y; Hojo, K; Ide, N; Iguchi, M; Kato, A; Matsumoto, M; Shichijo, M; Tanaka, H; Wada, T, 2010) |
| "A 40-year-old man with renal cell cancer diagnosed in 2005 and initially treated by radical nephrectomy presented in March 2007 with a recurrence with cerebral, mediastinal, and lung metastases." | ( Andrejak, M; Basille, D; Bentayeb, H; Boutemy, M; Dayen, C; Douadi, Y; Fournier, C; Garidi, R; Kanaan, M; Lecuyer, E, 2010) |
| "The treatment paradigm in advanced renal cell carcinoma (RCC) has changed in the recent years." | ( Anastasiou, I; Andreadis, C; Bamias, A; Christodoulou, C; Dafni, U; Dimopoulos, MA; Fountzilas, G; Karadimou, A; Kontovinis, L; Lainakis, G; Lampaki, S; Malettou, L; Papandreou, C; Papazisis, K; Razi, E; Skolarikos, A; Stravodimos, K; Syrigos, K; Timotheadou, E; Xanthakis, I, 2010) |
| "Inclusion criteria were: advanced renal cell carcinoma not amenable to surgery and treatment with Sunitinib." | ( Anastasiou, I; Andreadis, C; Bamias, A; Christodoulou, C; Dafni, U; Dimopoulos, MA; Fountzilas, G; Karadimou, A; Kontovinis, L; Lainakis, G; Lampaki, S; Malettou, L; Papandreou, C; Papazisis, K; Razi, E; Skolarikos, A; Stravodimos, K; Syrigos, K; Timotheadou, E; Xanthakis, I, 2010) |
| "A 74-year-old man with metastatic renal cell carcinoma and a history of cardiac failure was treated with sunitinib malate." | ( Haseke, N; Stadler, T; Staehler, M; Stief, CG; Zilinberg, K, 2010) |
| "Patients with metastatic renal cell carcinoma who had measurable disease and had not received previous cytotoxic or targeted therapy were treated with 6 mg/m(2) ixabepilone i." | ( Bates, S; Edgerly, M; Fojo, T; Huang, H; Huff, LM; Kotz, H; Menefee, M; Poruchynsky, M; Zhuang, S, 2010) |
| "We present a patient with metastatic renal cell carcinoma manifested as bilateral pulmonary nodules who developed a bilateral spontaneous pneumothorax 3 weeks after initiation of sunitinib therapy." | ( Fesler, MJ; Katta, A; Richart, JM; Tan, A; Vuong, G, 2010) |
| "Two groups of patients with metastatic renal cell carcinoma were eligible for this study: those with no previous treatment with targeted agents and those with previous treatment with sunitinib and/or sorafenib." | ( Burris, HA; Clark, BL; Hainsworth, JD; Spigel, DR; Waterhouse, D; Whorf, R, 2010) |
| "We describe a patient with terminal renal cell carcinoma who developed late iliac artery stent thrombosis despite dual chronic antiplatelet therapy with aspirin and clopidogrel." | ( Akgün, T; Can, MM; Karabay, CY; Kaymaz, C; Ozveren, O; Serebruany, V; Tanboğa, IH; Tokgöz, HC; Türkyilmaz, E, 2010) |
| "In the Treatment Approaches in Renal Cell Cancer Global Evaluation Trial (TARGET), sorafenib showed a significant progression-free survival advantage over placebo in patients with advanced RCC." | ( Bellmunt, J; Eisen, T; Fishman, M; Quinn, D, 2011) |
| "The patient had contracted renal cell carcinoma and had been treated by nephrectomy in 2003." | ( Hansen, T; Jäger, E; Koch, FP; Wagner, W; Walter, C, 2011) |
| "We present the case of a patient with renal cell carcinoma treated preoperatively with sorafenib." | ( Hara, T; Hatano, K; Inoue, H; Kinoshita, T; Kinouchi, T; Kobayashi, M; Nonomura, N; Takada, T, 2010) |
| "Advanced renal cell carcinoma is associated with a poor prognosis and is refractory to standard chemotherapy." | ( Albouy, B; Escudier, B; Gross Goupil, M; Massard, C, 2010) |
| "The advance of medical treatment in renal cell carcinoma (RCC) has fostered the development of diverse continuous oral therapies with tyrosine kinase inhibitors (TKI), among these sunitinib remains the mainstay of therapy for most of the patients." | ( Grünwald, V; Kalanovic, D; Merseburger, AS, 2010) |
| "Human renal cell carcinoma (RCC) is very resistant to chemotherapy." | ( Besch, R; Häcker, G; Weber, A; Zall, H; Zantl, N, 2010) |
| "Long-term stabilization of advanced renal cell carcinoma (RCC) by the sequence of sorafenib monotherapy followed by sunitinib and everolimus treatments in a man with multiple metastases is reported." | ( Beck, J; Bellmunt, J; Escudier, B, 2011) |
| "Patients with biopsy proven clear cell renal cell carcinoma were enrolled in the study and treated with 37." | ( Hellenthal, NJ; Kim, HL; Litwin, A; Penetrante, R; Teh, BT; Underwood, W; Wilding, GE; Zhang, S, 2010) |
| "Especially in renal cell carcinoma patients under sunitinib therapy and intravenous BP medication, oral mucositis should be observed closely because it could be a risk factor for BRONJ." | ( Eufinger, H; Hoefert, S, 2010) |
| "A 70-year-old man with metastatic renal cell carcinoma developed progressive liver metastases after 8 weeks of treatment with the multitargeted tyrosine kinase inhibitor (TKI) sunitinib." | ( Ginsberg, MS; Molina, AM; Motzer, RJ, 2011) |
| "Human renal cell carcinoma (HRCC) is characterized by a high level of resistance to all treatment modalities." | ( Ahn, KS; Bae, E; Chae, YS; Lee, C; Park, J; Won, NH; Yoon, SS, 2010) |
| "Clear cell renal cell cancer (ccRCC) prominently expresses vascular endothelial growth factor-A (VEGF-A), and new treatment strategies for renal cell cancer (RCC) aim at the inhibition of VEGF-VEGF receptor signaling." | ( Boerman, OC; Desar, IM; Leenders, WP; Mulders, PF; Oosterwijk, E; Oyen, WJ; Stillebroer, AB; van der Graaf, WT; van Herpen, CM, 2010) |
| "The treatment for metastatic renal cell carcinoma (RCC) has changed dramatically after the beginning of molecular-targeted therapies." | ( Asano, T; Hayakawa, M; Ito, K; Kaji, T; Kimura, F; Sumitomo, M; Takahashi, E; Umeda, S, 2010) |
| "Metastatic renal cell carcinoma (mRCC) is a difficult to treat malignancy and currently Sunitinib is a standard of care first-line therapy." | ( Board, R; Hawkins, R; O'Dwyer, J; Shablak, A, 2011) |
| "We present a patient with metastatic renal cell carcinoma treated with sunitinib, a multitargeted tyrosine kinase inhibitor." | ( Postema, PG; Regeer, MV; Richel, DJ; Stroes, ES; van der Valk, PR, 2011) |
| "Recent advancements in the treatment of renal cell carcinoma - focus on international guidelines." | ( Biró, K; Küronya, Z, 2010) |
| "Current treatment for metastatic renal cell cancer with vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKI) have provided improved overall survival, but complete responses are rare." | ( Arnott, J; Bruce, JY; Carducci, M; Eickhoff, J; Liu, G; Logan, T; Pili, R; Treston, A; Wilding, G, 2012) |
| "Current drug therapy for metastatic renal cell cancer (RCC) results in temporary disease control but not cure, necessitating continued investigation into alternative mechanistic approaches." | ( Alcazar, O; Hu, Z; Lindner, D; Negrotto, S; Ng, KP; Rini, B; Saunthararajah, Y; Triozzi, P, 2011) |
| "The European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study provided sorafenib to advanced renal cell carcinoma (RCC) patients in whom previous systemic therapy had failed." | ( Bajetta, E; Beck, J; Bokemeyer, C; Bracarda, S; Burock, K; Escudier, B; Keilholz, U; Mersmann, S; Negrier, S; Procopio, G; Richel, DJ; Staehler, M; Strauss, UP; Szczylik, C, 2011) |
| "Targeted therapy for advanced renal cell carcinoma (RCC) has recently expanded the available treatment options for patients with these malignancies." | ( Ravaud, A, 2011) |
| "Treatment options for renal cell carcinoma (RCC) have multiplied in the past 5 years." | ( Keisner, SV; Shah, SR, 2011) |
| "Patients with poor-prognosis advanced renal cell carcinoma treated with temsirolimus had an incremental gain of 48% (36." | ( Al, MJ; Alemao, E; Curiel, RE; Purvis, J; Rajagopalan, S; Yang, S, 2011) |
| "Metastatic renal cell carcinoma is resistant to conventional treatment with chemotherapy." | ( Arranz, JÁ; Climent, MÁ; González-Larriba, JL; León, L; Maroto, JP, 2011) |
| "Retrospective analysis of renal cell collecting duct carcinoma treated at our institution from January 2000 to June 2010, taking into account the patient's age, sex, reason for the consultation, oncological background, side of the affection, surgical treatment, other anatomopathological characteristics, tumour size, TNM clinical staging (2009), adjuvant treatment and survival time." | ( Hernández-Fernández, C; Herranz-Amo, F; Husillos, A; Lledó, E; Molina-Escudero, R; Subirá, D, 2011) |
| "RECORD-1 (Renal Cell cancer treatment with Oral RAD001 given Daily) was the pivotal multicenter, phase III, randomised, double-blind, placebo-controlled trial of everolimus that led to approval for patients with disease progression on or after treatment with VEGF-targeted agents." | ( Climent, MA; Creel, P; Dickow, B; Fischer, P; Gornell, SS; Meloni, F; Motzer, RJ; Osanto, S; Porta, C; Ravaud, A; Vaishampayan, U; White, DA, 2011) |
| "Celecoxib plus IFN-α in renal cell carcinoma (RCC) patients with maximally staining COX-2 tumors does not significantly enhance overall response rates over IFN monotherapy." | ( Dreicer, R; Elson, P; Finke, JH; Garcia, JA; Ireland, J; Rini, BI; Schwandt, A; Triozzi, P; Wyckhouse, J; Zhou, M, 2011) |
| "Patients with metastatic renal cell carcinoma and sunitinib-induced HTN defined by maximum SBP had better outcomes than those without treatment-induced HTN (objective response rate: 54." | ( Baum, MS; Chen, I; Cohen, DP; Figlin, RA; Gore, ME; Hariharan, S; Lu, DR; Motzer, RJ; Rini, BI, 2011) |
| "A 14-year-old girl with metastatic renal cell carcinoma was treated with nephrectomy, interferon, and several lines of the targeted agents sorafenib, bevacizumab, sunitinib, and everolimus, either alone or in combination." | ( Boldrini, R; Cortesi, E; De Pasquale, MD; Donfrancesco, A; Ilari, I; Jenkner, A; Pessolano, R, 2011) |
| "We enrolled 45 patients with metastatic renal cell carcinoma (RCC) at a progressive disease between March 2003 and April 2008 to assess the impact of an anti-inflammatory treatment regime in combination with metronomic low-dose chemotherapy." | ( Andreesen, R; Berand, A; Bross, K; Grassinger, J; Reichle, A; Rogenhofer, S; Schrettenbrunner, I; Suedhoff, T; Vogelhuber, M; Walter, B; Wieland, WF; Wilke, J, 2012) |
| "Metastatic renal cell carcinoma (RCC) is a molecularly heterogeneous disease that is intrinsically resistant to chemotherapy and radiotherapy." | ( Al-Lazikani, B; Alumkal, JJ; Atkins, KM; Beer, TM; Brewer, D; Cassidy, AM; De-Bono, J; Gao, L; Geng, H; Gore, ME; Graf, M; Huang, P; Kaye, SB; Larkin, J; Moch, H; Nelson, P; Qian, DZ; Sawyers, CL; Schraml, P; Suwaki, N; Swabey, K; Thomas, G; Thomas, GV; Vanhecke, E; Workman, P, 2011) |
| "Nephrectomized renal cell carcinoma patients with lung metastasis were treated with interleukin-2 (0." | ( Akaza, H; Fujioka, T; Kitamura, T; Miki, T; Naito, S; Nakamura, Y; Ozono, S; Tomita, Y; Tsukamoto, T; Zembutsu, H, 2011) |
| "Combining targeted treatments for renal cell carcinoma has been suggested as a possible method to improve treatment efficacy." | ( Bay, JO; Blanc, E; Chevreau, C; Delva, R; Escudier, B; Ferlay, C; Geoffrois, L; Gravis, G; Laguerre, B; Legouffe, E; Négrier, S; Pérol, D; Rolland, F; Sevin, E, 2011) |
| "Patients with advanced clear cell renal carcinoma who had received previous therapy with at least one angiogenesis inhibitor and one mTOR inhibitor were treated with panobinostat 45 mg orally twice a week, and were reevaluated after 8 weeks." | ( Arrowsmith, ER; Boccia, RV; Burris, HA; Hainsworth, JD; Infante, JR; Spigel, DR, 2011) |
| "In metastatic renal cell carcinoma (mRCC) patients treated with targeted agents and their primary tumor (PT) in situ, early PT decrease in size correlates with improved overall PT response, but the effect on overall survival (OS) is unknown." | ( Abel, EJ; Culp, SH; Matin, SF; Tamboli, P; Tannir, NM; Wood, CG, 2011) |
| "Patients with metastatic renal cell carcinoma (mRCC) received sunitinib 50 mg orally once daily in 6-week cycles according to a 4-week on/2-week off treatment schedule." | ( Filipiak, KJ; Langiewicz, P; Nurzyński, P; Opolski, G; Szczylik, C; Szmit, S; Zaborowska, M; Złnierek, J, 2012) |
| "The perspectives of renal cell carcinoma (RCC) treatment have improved with the development of targeted molecular therapies against VEGFR/VEGF-mediated angiogenesis and mTOR." | ( Joly, F, 2011) |
| "Sensitization of renal adenocarcinoma cells to TRAIL was apparent after as little as 1-4 h pretreatment and did not require continued presence of cucurbitacin." | ( Booth, NL; Brooks, AD; Henrich, CJ; Lowery, EM; McMahon, JB; Pompei, RJ; Sayers, TJ; Thomas, CL, 2012) |
| "Therapy of patients with metastatic renal cell carcinoma (mRCC) requires sequential use of several agents with different mechanisms and minimal cross-resistance between the different agents." | ( Brion, N; Paule, B, 2011) |
| "The treatment of advanced renal cell carcinoma has been revolutionised by targeted therapy with drugs that block angiogenesis." | ( Castellano, D; Cella, D; Chen, C; Escudier, B; Gorbunova, VA; Gore, ME; Hutson, TE; Kaprin, A; Kim, S; Lim, HY; Michaelson, MD; Motzer, RJ; Negrier, S; Ou, YC; Rini, BI; Rosbrook, B; Rusakov, IG; Szczylik, C; Tarazi, J; Tomczak, P; Uemura, H, 2011) |
| "Data from patients with metastatic renal cell carcinoma (mRCC) treated with anti-VEGF therapy were collected through the International mRCC Database Consortium from 12 centers." | ( Bjarnason, GA; Choueiri, TK; Donskov, F; Heng, DY; Knox, JJ; Kollmannsberger, C; Mackenzie, MJ; North, S; Rini, BI; Tan, MH; Vaishampayan, UN; Wang, Y; Wood, L, 2012) |
| "For patients with metastatic renal cell cancer (mRCC) who progressed on vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor therapy, the orally administered mammalian target of rapamycin (mTOR) inhibitor everolimus has been shown to prolong progression free survival." | ( de Gruijl, TD; Haanen, JB; Huijts, CM; Pijpers, LS; Santegoets, SJ; van den Eertwegh, AJ; van der Vliet, HJ; Verheul, HM, 2011) |
| "We reviewed the outcomes of metastatic renal cell carcinoma patients with the primary tumor in situ who initially underwent interferon-α-based immunotherapy to evaluate the effect of this therapy on metastatic sites as well as primary kidney tumor and survival." | ( Abe, T; Maruyama, S; Nonomura, K; Sato, S; Sazawa, A; Shindo, J; Shinohara, N; Suzuki, S, 2012) |
| "In patients with metastasized renal cell carcinoma, hematologic toxicity after treatment with (177)Lu-cG250 can be predicted on the basis of administered activity and whole-body and red marrow-absorbed dose." | ( Boerman, OC; Mulders, PF; O'Donoghue, JA; Oosterwijk, E; Oyen, WJ; Stillebroer, AB; Visser, EP; Zegers, CM, 2012) |
| "We report a case of advanced sarcomatoid renal cell carcinoma (RCC) effectively treated with sunitinib." | ( Ishida, H; Ito, H; Itoh, H; Tsuchiyama, K; Yokoyama, O, 2011) |
| "Elderly patients with metastatic renal cell carcinoma (mRCC) may require special treatment considerations, particularly when comorbidities are present." | ( Anak, O; Bracarda, S; Calvo, E; Climent, MA; Escudier, B; Grünwald, V; Hutson, TE; Kim, D; Motzer, RJ; Osanto, S; Panneerselvam, A; Porta, C; Ravaud, A; Vaishampayan, U, 2012) |
| "Seven patients with metastatic renal cell carcinoma, which continued to progress despite treatment with sunitinib or sorafenib, developed interstitial lung disease after treatment with everolimus." | ( Asano, K; Kaneko, G; Mikami, S; Mizuno, R; Nagata, H; Oya, M, 2012) |
| "Initially thought to have metastatic renal cell carcinoma based on computed tomography imaging and referred for immunotherapy, a positron emission tomography/computed tomography scan demonstrated different levels of radiotracer activity in the primary site and the presumed pulmonary metastatic sites." | ( Dechet, C; Heilbrun, M; Willis, H, 2011) |
| "Metastatic renal cell carcinoma (RCC) is highly resistant to systemic chemotherapy." | ( Chen, JY; Chuang, SJ; Hour, TC; Huang, CY; Kang, WY; Lai, MK; Lin, YC; Pu, YS; Shiu, YS; Tsai, YC; Wu, WJ; Yu, HJ, 2012) |
| "Approximately 30% of patients with renal cell cancer (RCC) develop bone metastasis causing skeletal-related events (SRE): pathologic fracture, spinal cord compression, surgery to bone and radiotherapy." | ( Birkholz, K; Gruenwald, V; Kindler, M; May, C; Miller, K; Ruebel, A; Schultze-Seemann, W; Schulze, M; Stenzl, A; Strauss, A; Tunn, UW; Wirth, MP; Zantl, N, 2012) |
| "Patients with metastatic renal cell carcinoma (mRCC) are often treated sequentially with targeted agents, although the optimal strategy is not known." | ( Abrahamova, J; Bortlicek, Z; Buchler, T; Melichar, B; Pavlik, T; Poprach, A; Vyzula, R, 2012) |
| "Non-clear cell renal cell carcinomas (nccRCCs) comprise a heterogenous and poorly characterized group of tumor types for which few treatments have been approved." | ( Albiges, L; Escudier, B; Molinie, V, 2012) |
| "Human clear cell renal cell carcinoma (CCC) remains resistant to treatments despite the progress in targeted therapies." | ( Barthelmebs, M; Béraud, C; Brasse, D; Coquard, C; Dormoy, V; Jacqmin, D; Lang, H; Lindner, V; Massfelder, T, 2012) |
| "Major progress in treatment of renal cell carcinoma (RCC) has occurred in the past decade." | ( Bernhard, JC; Gross-Goupil, M; Ravaud, A, 2012) |
| "A 74-year-old male with clear cell renal cell carcinoma with pulmonary metastases was treated with sorafenib to good effect." | ( O'Connor, TM; O'Reilly, SP; Power, DG; Teo, M, 2012) |
| "Retrospective study on all the renal cell carcinoma patients with bone metastases treated with sunitinib or sorafenib between November 2005 and June 2012 at the University Hospitals Leuven and AZ Groeninge in Kortrijk." | ( Berkers, J; Beuselinck, B; Body, JJ; Debruyne, P; Dumez, H; Elaidi, R; Karadimou, A; Lerut, E; Paridaens, R; Rogiers, A; Schöffski, P; Van Cann, T; Van Poppel, H; Willems, L; Wolter, P, 2012) |
| "We analyzed renal cell carcinoma (RCC) brain metastasis (BM) risk factors and compared BM occurrence in metastatic RCC (mRCC) treated with or without anti-angiogenic agents (AA)." | ( Adenis, A; Alt, M; Caty, A; Fumagalli, I; Penel, N; Vanhuyse, M; Zini, L, 2012) |
| "Current treatments for metastatic renal cell carcinoma do not extend survival beyond a few months." | ( Benitez, A; Bowen, T; Lokeshwar, VB; Shamaldevi, N; Yates, TJ, 2013) |
| "Pituitary metastasis from renal cell carcinoma is rare and has never been reported for renal cell carcinoma primarily treated with sorafenib." | ( Hu, GY; Yang, L; Yu, SY, 2013) |
| "Patients diagnosed with metastatic renal cell carcinoma (mRCC) are currently treated with oral tyrosine kinase inhibitors (TKIs)." | ( Arima, K; Kanda, H; Masui, S; Sugimura, Y; Yamada, Y, 2012) |
| "The case of a patient with metastatic renal cell cancer (RCC) who developed recall pneumonitis on the first cycle of systemic sunitinib treatment is reported here." | ( Harada, S; Kitsukawa, S; Kozuka, T; Kudo, K; Miyazawa, K; Sukegawa, G; Yamamoto, S; Yonese, J; Yuasa, T, 2013) |
| "Treatment of metastatic renal cell carcinoma has radically changed during the last decade with the approval of new drugs, antiangiogenic agents and mammalian targets of rapamycin (m-TOR) inhibitors." | ( Bernhard, JC; Daste, A; Gross-Goupil, M; Ravaud, A; Roca, S, 2014) |
| "Patients with advanced or metastatic renal cell carcinoma (RCC) with predominant clear cell histology were treated with oral dovitinib 500 or 600 mg/day (5-days-on/2-days-off schedule)." | ( Angevin, E; Castellano, D; Chang, J; Escudier, B; Gschwend, JE; Harzstark, A; Kay, A; Lin, CC; Lopez-Martin, JA; Sen, P; Shi, M; Soria, JC, 2013) |
| "To compare outcomes of metastatic renal cell carcinoma (mRCC) patients who underwent primary cytoreductive nephrectomy (CRN), followed by adjuvant sunitinib therapy, vs those who underwent primary sunitinib therapy before planned CRN." | ( Cohen, SA; Derweesh, IH; Kane, CJ; Kopp, RP; Liss, MA; Mehrazin, R; Millard, F; Palazzi, KL; Park, SK; Patel, N; Patterson, AL; Raheem, OA; Stroup, SP, 2013) |
| "A 76-year-old female with advanced renal cell carcinoma had been treated with everolimus for 3 months." | ( Gemma, A; Kimura, G; Kondo, Y; Minegishi, Y; Miura, Y; Nagayama, M; Noro, R; Ogushi, S; Saito, Y; Suzuki, Y, 2013) |
| "We describe three cases of metastatic renal cell carcinoma patients (a 53-year-old male, a 70-year-old woman, and a 65-year-old woman) who received a shortened 3-week sunitinib administration schedule, 2 weeks daily administration followed by 1 week of rest (2/1) due to toxicities developed on the classic 6-week schedule, which would have required a temporary treatment interruption or a dose reduction." | ( Brugia, M; Cerullo, C; Neri, B; Rangan, S; Rediti, M; Tassi, R; Vannini, A, 2012) |
| "We retrospectively analyzed metastatic renal cell carcinoma (RCC) patients treated with 3 targeted agents." | ( Calvani, N; Chiuri, V; Cinieri, S; Fedele, P; Gnoni, A; Lorusso, V; Maiello, E; Morelli, F; Orlando, L; Scavelli, C, 2013) |
| "With seven agents approved for renal cell carcinoma within the past few years, there has undoubtedly been progress in treating this disease." | ( De Tursi, M; Felici, A; Lo Re, G; Milella, M; Ricotta, R; Ruggeri, EM; Sabbatini, R; Santini, D; Santoni, M; Vaccaro, V, 2013) |
| "We report a case of metastatic renal cell carcinoma (RCC) treated with cytoreductive nephrectomy, cytokine therapy, and molecular targeted therapy followed by metastasectomy." | ( Ikehata, Y; Kitamura, H; Masumori, N; Takahashi, S; Tsukamoto, T, 2013) |
| "A total of 136 patients with advanced renal cell carcinoma were treated with sunitinib at our hospital from 2008 to 2011." | ( Dai, B; Hong, YP; Lin, GW; Ma, CG; Qin, XJ; Shen, YJ; Xiao, WJ; Yao, XD; Ye, DW; Zhang, HL; Zhang, SL; Zhu, Y; Zhu, YP, 2013) |
| "Thirty-six Japanese metastatic renal cell carcinoma patients treated with sorafenib were enrolled and divided into the groups with or without Hand-Foot skin reaction." | ( Kobayashi, M; Komatsu, K; Kubo, T; Kurokawa, S; Morita, T; Nakano, K; Natsui, S; Nukui, A, 2013) |
| "We describe a patient with metastatic renal cell carcinoma and a history of Crohn's disease who was treated with sunitinib and developed a severe exacerbation of Crohn's disease." | ( Boers-Sonderen, MJ; Hoentjen, F; Jacobs, JF; Mulder, SF; Nagtegaal, ID; van Herpen, CM; Wanten, GJ, 2014) |
| "Patients with metastatic renal cell carcinoma (mRCC) and a good performance status typically receive an anti-vascular endothelial growth factor receptor (VEGFR) TKI (sunitinib or pazopanib) as initial therapy." | ( Broom, RJ; Dranitsaris, G; Schmitz, S, 2013) |
| "Patients with metastatic clear cell renal cell carcinoma (ccRCC) are frequently treated with tyrosine kinase inhibitors (TKI) such as sunitinib." | ( Dornbusch, J; Erdmann, K; Froehner, M; Fuessel, S; Meinhardt, M; Wirth, MP; Wolff, I; Zacharis, A; Zastrow, S, 2013) |
| "Patients with progressive renal cell carcinoma who undergo sunitinib treatment, experience many adverse events (AEs), including thrombopenia and hypertension." | ( Arakawa-Todo, M; Hasegawa, T; Kajikawa, K; Kato, Y; Kobayashi, I; Matsuura, K; Nakamura, K; Nishikawa, G; Saito, H; Sumitomo, M; Tsukiyama, I; Yamada, Y; Yoshizawa, T; Zennami, K, 2013) |
| "To compare outcomes of metastatic renal cell carcinoma (mRCC) patients treated with everolimus, temsirolimus, and sorafenib following initial treatment with a tyrosine kinase inhibitor (TKI) in community and academic practices throughout the US." | ( George, DJ; Liu, NS; Liu, Z; Qi, CZ; Signorovitch, JE; Wang, X; Wong, MK; Yang, H, 2014) |
| "The life expectancy in metastatic renal cell carcinoma patients treated with targeted therapies can be influenced by the time spent on treatment, and the current focus of clinical research in this field appears to be on extending the time on treatment while limiting toxicities." | ( De Placido, S; Di Lorenzo, G, 2014) |
| "Whoever the renal cell carcinoma incidence is low but it seems it is more complicated than the other cancers in terms of pathophysiology and treatments." | ( bin-Noordin, MI; Davoudi, ET; Javar, HA; Kadivar, A; Sabeti, B, 2014) |
| "Treatment of metastatic renal cell carcinoma (mRCC) has improved significantly with the advent of agents targeting the mTOR pathway, such as temsirolimus and everolimus." | ( Amantini, C; Berardi, R; Burattini, L; Cascinu, S; Conti, A; Nabissi, M; Pantano, F; Santini, D; Santoni, G; Santoni, M; Tonini, G; Zoccoli, A, 2014) |
| "Chemotherapy for collecting duct carcinoma (CDC) has demonstrated only limited efficacy in the advanced setting." | ( Colecchia, M; De Braud, F; Garanzini, E; Grassi, P; Iacovelli, R; Procopio, G; Testa, I; Torelli, T; Verzoni, E, 2014) |
| "Treatment of metastatic renal cell carcinoma (mRCC) with sunitinib is often associated with toxicity necessitating dose reduction." | ( Dreicer, R; Elson, P; Garcia, JA; Mittal, K; Najjar, YG; Rini, BI; Wood, L, 2014) |
| "metastatic renal cell cancer (mRCC) or GIST patients treated with sunitinib or sorafenib (VEGFR TKI patients n = 30); 2." | ( Bertens, D; Desar, IM; Kessels, RP; Langenhuijsen, JF; Mulder, SF; Mulders, PF; Punt, CJ; van Herpen, CM; van Spronsen, DJ; Vissers, KC, 2014) |
| "A new approach in the treatment of clear cell renal carcinoma (ccRCC) is radioimmunotherapy (RIT) using anti-carbonic anhydrase IX (CAIX) antibody G250." | ( Boerman, OC; Bos, DL; Mulders, PF; Muselaers, CH; Oosterwijk, E; Oyen, WJ, 2014) |
| "A phase II trial in advanced renal cell carcinoma (RCC) found no benefit in efficacy or safety between patients receiving oral sunitinib 50 mg/day for 4 weeks followed by 2-week off-treatment (Schedule 4/2) and those receiving 37." | ( Beaumont, JL; Bhattacharyya, H; Cella, D; Hahn, EA; Jensen, SE; Korytowsky, B; Motzer, R, 2014) |
| "Clear-cell renal cell carcinoma is a highly treatment-resistant tumor type." | ( Gao, C; Peng, FH; Peng, LK, 2014) |
| "PREDICT (Patient characteristics in REnal cell carcinoma and Daily practICe Treatment with sorafenib) was a prospective, noninterventional study of open-label sorafenib for the treatment of advanced RCC conducted in 18 countries." | ( Ahn, H; Böckenhoff, A; Escudier, B; Guo, J; Jäger, D; Korbenfeld, E; Leonhartsberger, N; Ma, JH; Mardiak, J; Stauch, K; Ye, DW; Yu, J; Zemanova, M, 2015) |
| "Human renal carcinoma cell lines 786-O, ACHN, and Caki-1 were treated with sunitinib or elacridar alone, or in combination." | ( Arano, Y; Gushimiyagi, K; Kashiba, T; Nomura, Y; Sato, H; Sekine, Y; Siddig, S; Suzuki, S; Uehara, T; Ueno, K; Uzu, M; Yamaura, K, 2015) |
| "We report a case of renal cell carcinoma diagnosed after a patient was treated successfully with intravenous cyclophosphamide for her active proliferative lupus nephritis (classes III and V)." | ( Wong, KW, 2015) |
| "However, mean numbers of renal carcinomas were statistically significantly decreased in the lycopene-treated rats (P<0." | ( Bilir, B; Carthon, B; Ciccone, K; Cross, B; Harris, W; Kucuk, O; Master, V; Mohammad, R; Moreno, CS; Osunkoya, AO; Sahin, K; Sahin, N; Suleiman, S; Walker, CL; Wertz, K, 2015) |
| "In 769-P and ACHN renal carcinoma cells treatment with 30 μM RAC caused 69." | ( Cui, L; Li, HJ; Li, QC; Liang, Y; Liu, S; Wang, X, 2015) |
| "A total of 361 patients with metastatic clear cell renal cell carcinoma were randomly assigned equally to arm A (bevacizumab monotherapy 10 mg/kg intravenously [IV] every 2 weeks), B (bevacizumab 10 mg/kg IV every 2 weeks and temsirolimus 25 mg IV every week), C (bevacizumab 5 mg/kg IV every 2 weeks and sorafenib 200 mg orally twice daily on days 1 to 5, 8 to 12, 15 to 19, and 22 to 26), or D (sorafenib 200 mg twice daily and temsirolimus 25 mg IV weekly)." | ( Atkins, MB; DiPaola, RS; Dutcher, JJ; Flaherty, KT; George, DJ; Manola, JB; Margolin, KA; McDermott, DF; Pins, M, 2015) |
| "In a preclinical model of renal cell cancer, systemic administration of DSR-6434 dosed once weekly resulted in a significant anti-tumor response." | ( Dovedi, SJ; Harada, H; Hirose, Y; Jewsbury, PJ; Koga-Yamakawa, E; Li, CJ; Murata, M; Ota, Y; Robinson, DT; Sugaru, E; Umehara, H; Wilkinson, RW; Yamamoto, S, 2015) |
| "Mice transplanted with 6 lines of renal cell carcinoma (RCC) were injected with doxorubicin to observe the effect of the chemotherapy on tumor growth." | ( Brugarolas, J; Chen, W; Collins, R; Denard, B; Naina, H; Pavia-Jimenez, A; Williams, NS; Ye, J, 2015) |
| "If the Phase III Advanced Renal Cell Carcinoma trial is positive, this treatment modality will provide a significant survival benefit with minimal toxicity and could change the standard of care for ccmRCC." | ( Figlin, RA, 2015) |
| "Sorafenib for the treatment of advanced renal cell carcinoma under the labeled dose was feasible in daily medical practice, for its acceptable toxicity profile and favorable clinical benefit that were consistent with those in clinical trials." | ( Adachi, M; Akaza, H; Gemma, A; Hyodo, I; Iijima, M; Inuyama, L; Itoh, H; Okayama, Y; Oya, M; Sunaya, T, 2015) |
| "Metastatic renal cell carcinoma (mRCC) patients receiving first-line sunitinib typically survive >2 yr, with chronic treatment sometimes extending to ≥6 yr." | ( Charles, LP; DeAnnuntis, L; Escudier, B; Gore, ME; Hariharan, S; Motzer, RJ; Porta, C; Rini, BI; Yang, L, 2016) |
| "Sunitinib is widely used for treating renal cell carcinoma (RCC)." | ( Hirai, M; Hirano, T; Mizumoto, A; Nakagawa, T; Nakayama, Y; Takara, K; Yamamoto, K, 2015) |
| "Metastatic renal cell carcinomas (mRCC) are highly vascularized tumors that are a paradigm for the treatment with antiangiogenesis drugs targeting the vascular endothelial growth factor (VEGF) pathway." | ( Auberger, P; Belaid, A; Benhida, R; Colosetti, P; Cormerais, Y; Dufies, M; Giuliano, S; Grépin, R; Lacas-Gervais, S; Martin, A; Mazure, NM; Mograbi, B; Pagès, G; Parola, J, 2015) |
| "Metastatic renal cell carcinoma has a poor prognosis and an intrinsic resistance to standard treatment." | ( Agarwal, N; Beardmore, B; Boucher, K; Butterfield, RI; Hoffman, JM; Horn, KP; Kadrmas, DJ; Morton, KA; Yap, JT, 2015) |
| "Surgical treatment for metastatic renal cell carcinoma should also be reconsidered in the light of the effect of targeted drugs." | ( Tomita, Y, 2016) |
| "Currently, metastatic renal cell carcinoma is treated with sequential single agents targeting VEGF or mTOR." | ( Dutcus, C; Eisen, T; Glen, H; Hutson, TE; Jassem, J; Kim, HJ; Kremer, A; Larkin, J; Maroto, JP; Melichar, B; Mellado, B; Michaelson, MD; Molina, A; Motzer, RJ; Tomasek, J; Wood, K; Zolnierek, J, 2015) |
| "Metastatic renal cell carcinoma (mRCC) prognostic models may be improved by incorporating treatment-induced toxicities." | ( Bjarnason, GA; Cohen, DP; Davis, MP; Donskov, F; Goldstein, D; Lin, X; Michaelson, MD; Motzer, RJ; Puzanov, I; Rini, BI; Wiltshire, R, 2015) |
| "Metastatic clear-cell renal cell carcinoma patients with available fresh-frozen tumour and treated with anti-VEGFR-TKIs." | ( Albiges, L; Beuselinck, B; Couchy, G; De Reynies, A; Elaidi, R; Gravis, G; Jean-Baptiste, J; Job, S; Joniau, S; Lerut, E; Méjean, A; Oudard, S; Patard, JJ; Rousseau, B; Schöffski, P; Théodore, C; Verkarre, V; Wolter, P; Zucman-Rossi, J, 2015) |
| "Advanced renal cell carcinoma is treated with mammalian target of rapamycin (mTOR) inhibitors or tyrosine kinase inhibitors (TKIs)." | ( Deguchi, T; Fujita, Y; Hayashi, H; Ito, M; Itoh, Y; Kameyama, K; Kato, T; Kawakami, K; Mizutani, K; Ohno, Y; Sugiyama, T; Tomoda, M, 2015) |
| "Patients with metastatic renal carcinoma (mRCC) treated with first-line pazopanib were not included in the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic model." | ( Arranz Arija, JA; Basterretxea Badiola, L; Borrega García, P; Castellano Gaunas, DE; Chirivella González, I; Fernández Parra, EM; Gajate Borau, P; García Carbonero, I; García Domínguez, R; García Marrero, RD; González del Alba, A; González Larriba, JL; Jiménez Gallego, P; Juan Fita, MJ; Jurado García, JM; Lambea Sorrosal, JJ; Lázaro Quintela, M; León-Mateos, L; López Brea, M; Maximiano Alonso, C; Meana García, JA; Méndez Vidal, MJ; Molins Palau, C; Pérez-Valderrama, B; Pinto Marín, A; Puertas Álvarez, JL; Reig Torras, O; Rodríguez Sánchez, A; Rubio Romero, G; Santander Lobera, C; Suárez Rodríguez, C; Vázquez Estévez, S; Vélez de Mendizábal, E; Villa Guzmán, JC, 2016) |
| "Non-clear cell renal cell carcinomas are histologically and genetically diverse kidney cancers with variable prognoses, and their optimum initial treatment is unknown." | ( Armstrong, AJ; Broderick, S; Eisen, T; Garcia, JA; George, DJ; Hainsworth, JD; Halabi, S; Hawkins, RE; Jones, RJ; Kollmannsberger, CK; Logan, TF; Lusk, CM; Oberg, S; Pickering, LM; Picus, J; Protheroe, A; Puzanov, I; Ryan, CW; Stadler, WM; Vaishampayan, UN, 2016) |
| "The treatment of metastatic renal cell carcinoma (mRCC) has largely improved over the last decade, due to the availability of several targeted agents (TAs)." | ( Aurilio, G; Cossu Rocca, M; Cullurà, D; de Cobelli, O; Iacovelli, R; Nolé, F; Santoni, M; Verri, E, 2016) |
| "The role of adjuvant therapy for renal cell carcinoma (RCC) after surgical resection has been evaluated in numerous randomized and nonrandomized studies using systemic therapies with distinct mechanisms of action." | ( Galsky, MD; Mehrazin, R; Sfakianos, J; Tsao, CK, 2016) |
| "Patients with advanced renal cell carcinoma of any pathologic subtype treated with at least one cycle (four weeks) of axitinib followed by at least one subsequent targeted therapy were investigated in a retrospective analysis." | ( Chittoria, N; Dreicer, R; Elson, P; Garcia, JA; Haddad, H; Jonasch, E; Rini, BI; Tannir, NM; Wood, LS, 2016) |
| "Treatment of metastatic renal cell carcinoma (mRCC) with agents that block signaling through vascular endothelial growth factor receptor 2 (VEGFR2) induces disease regression or stabilization in some patients; however, these responses tend to be short-lived." | ( Alimzhanov, M; Alsop, DC; Atkins, MB; Bhasin, MK; Bhatt, RS; Callea, M; Khanna, P; Kumar, R; Mier, JW; Pearsall, RS; Signoretti, S; Solban, N; Song, J; Wang, X, 2016) |
| "The treatment landscape for renal cell carcinoma (RCC) is a dynamic process that has seen considerable change in recent years." | ( Figlin, RA; Hutson, TE; Rini, BI; Thoreson, GR, 2016) |
| "Despite advances in metastatic renal cell carcinoma (mRCC) treatments, patients eventually progress and develop resistance to therapies targeting a single pathway." | ( Glen, H, 2016) |
| "We report the case of a man affected by renal cell carcinoma with vertebral metastases, who presented a radiological complete response after systemic treatment with everolimus." | ( Baldazzi, V; Becherini, C; Detti, B; Francolini, G; Giacomelli, I; Greto, D; Livi, L; Meattini, I; Olmetto, E; Scartoni, D; Simontacchi, G, 2016) |
| "In metastatic chromophobe renal cell carcinoma, sunitinib therapy may be associated with similar outcome and toxicities as in metastatic clear cell renal cell carcinoma." | ( Berger, R; Carducci, MA; Eisenberger, MA; Gottfried, M; Hammers, H; Keizman, D; Lee, JL; Mermershtain, W; Neiman, V; Neumann, A; Peer, A; Rosenbaum, E; Rouvinov, K; Sarid, D; Sella, A; Sinibaldi, V; Yildiz, I, 2016) |
| "The treatment of metastatic renal cell carcinoma (mRCC) has markedly improved over the last few years with the introduction of several targeted agents in clinical practice." | ( de Braud, F; Grassi, P; Mennitto, A; Procopio, G; Ratta, R; Verzoni, E, 2016) |
| "Patients with renal cell cancer who develop hypothyreosis during tyrosine kinase inhibitor (TKI) treatment have statistically longer survival." | ( Brzezianska-Lasota, E; Czarnecka, AM; Czarnecka, KH; Lewicki, S; Matak, D; Szczylik, C; Szymanski, L; Zdanowski, R, 2016) |
| "Survival of patients with metastatic renal cell carcinoma (mRCC) has improved since the advent of targeted therapy." | ( Calvo, E; Escudier, B; Grünwald, V; Heng, DY; Schmidinger, M, 2016) |
| "Metastatic renal cell carcinoma (RCC) patients are commonly treated with vascular endothelial growth factor (VEGF) inhibitors or mammalian target of rapamycin inhibitors." | ( Berger, MF; Bhanot, U; Bouvier, N; Chen, D; Chen, YB; Cheng, EH; Chevinsky, MS; Hakimi, AA; Hsieh, JJ; Huberman, KH; Knox, J; Lee, W; Marker, M; Motzer, RJ; Patel, P; Pinciroli, P; Redzematovic, A; Selcuklu, SD; Socci, ND; Viale, A; Voi, M; Voss, MH; Wang, PI; Weinhold, N; Won, HH; You, D, 2017) |
| "The European Association of Urology Renal Cell Carcinoma (RCC) guidelines panel updated their recommendation on adjuvant therapy in unfavourable, clinically nonmetastatic RCC following the recently reported results of a second randomised controlled phase 3 trial comparing 1-yr sunitinib to placebo for high-risk RCC after nephrectomy (S-TRAC)." | ( Albiges, L; Bensalah, K; Bex, A; Dabestani, S; Giles, RH; Hofmann, F; Hora, M; Kuczyk, MA; Lam, TB; Ljungberg, B; Marconi, L; Merseburger, AS; Powles, T; Staehler, M; Volpe, A, 2017) |
| "The current treatment of metastatic renal cell carcinoma (mRCC) revolves around targeted agents, which have resulted in a median overall survival of 22 to 26 months in registration trials." | ( Joshi, A; Kannan, RA; Kothari, R; Menon, S; Noronha, V; Patil, VM; Popat, P; Prabhash, K; Ramaswamy, A; Sable, N; Sahu, A, 2017) |
| "Metastatic renal cell carcinoma is a largely incurable disease, and existing treatments targeting angiogenesis and tyrosine kinase receptors are only partially effective." | ( Gobe, GC; He, Y; Hooper, J; Jeffery, PL; Lourie, R; McGuckin, MA; Morais, C; Ng, CP; Oancea, I; Seim, I; Shah, ET; Sheng, Y; Wong, KY, 2017) |
| "Treatment of patients with metastatic renal cell carcinoma (mRCC) has improved substantially since the introduction of targeted therapies, but no predictive biomarkers are available." | ( Bono, P; Hänninen, E; Joensuu, H; Peltola, KJ; Penttilä, P; Rautiola, J; Ristimäki, A, 2017) |
| "Clear cell renal cell cancer (ccRCC) is not sensitive to radiotherapy or chemotherapy, and treatment of patients with distant metastasis relies on targeted therapy." | ( Feng, H; Liu, K; Liu, Y; Yang, Z; Zhang, X; Zhang, Y; Zhu, Y, 2017) |
| "The dataset included 64 metastatic renal cell carcinoma patients (mRCC) treated with oral axitinib." | ( Amantea, MA; Friberg, LE; Karlsson, MO; Schindler, E, 2017) |
| "For patients with metastatic renal cell cancer (mRCC), treatment choice is mainly based on clinical parameters." | ( Ambert, V; Cambon-Thomsen, A; Castellano, D; Diekstra, MHM; Eisen, T; Fritsch, A; Garcia Donas, J; Guarch Troyas, R; Guchelaar, HJ; Hartmann, A; Hulsbergen-van de Kaa, C; Jaehde, U; Junker, K; Kiemeney, LALM; Martinez-Cardus, A; Masson, G; Maurits, JSF; Oosterwijk, E; Oosterwijk-Wakka, J; Oskarsdottir, A; Radu, MT; Rafnar, T; Rodriguez-Antona, C; Roessler, M; Ruijtenbeek, R; Stefansson, K; van der Zanden, LFM; Vermeulen, SH; Warren, A; Wessels, L, 2017) |
| "A 75-year-old man with a metastatic renal cell carcinoma was admitted for rapidly progressive weakness and numbness in the extremities after the first course of pazopanib therapy." | ( Araki, K; Fujikura, M; Koshikawa, H; Kurita, A; Suzuki, M; Tsukie, T, 2017) |
| "Metastatic renal cell carcinoma (MRCC) exhibits primary resistance to both chemotherapy and radiotherapy." | ( Gao, Q; Lin, H; Song, Y; Yang, Y; Zhao, L, 2017) |
| "Accrual to renal cell carcinoma trials remains a challenge despite the lack of prolonged response to the available treatments." | ( Balasubramaniam, S; Burotto, M; Drabkin, H; Edgerly, M; Fojo, T; Gormaz, JG; Madan, R; O'Sullivan, C; Velarde, M, 2017) |
| "Treatment of metastatic renal cell carcinoma (mRCC) remains suboptimal." | ( Balasubramaniam, S; Burotto, M; Drabkin, H; Edgerly, M; Fojo, T; Gormaz, JG; Madan, R; O'Sullivan, C; Velarde, M, 2017) |
| "Matched patient-derived clear cell renal cell carcinoma xenografts and cell lines from responsive and refractory patients treated with sunitinib were established and evaluated for pharmacologic response to anti-vascular endothelial growth factor treatment." | ( Aras, O; Arcila, ME; Becerra, MF; Benfante, N; Boland, PJ; Casuscelli, J; Chawla, M; Chen, YB; Cheng, EH; Coleman, JA; Dong, Y; Durack, JC; Fabbri, N; Feldman, DR; Hakimi, AA; Han, S; Healey, JH; Hsieh, JJ; Lee, CH; Manley, BJ; Motzer, RJ; Redzematovic, A; Reznik, E; Russo, P; Tennenbaum, DM; Voss, MH, 2017) |
| "A 64-year-old Japanese man with renal cell carcinoma (RCC) and tumour thrombus in the inferior vena cava was treated with sunitinib." | ( Ishikawa, S; Katagiri, A; Kazama, A; Mizusawa, T, 2017) |
| "Only for renal cell carcinoma (RCC) in a local stage curative treatment option by surgical resection exists." | ( Bedke, J; Hegemann, M; Kröger, N; Kruck, S; Notohamiprodjo, M; Stenzl, A; Stühler, V; Todenhöfer, T, 2018) |
| "Kidney cancer (Renal Cell Carcinoma (RCC)) is one of the most deadly malignancies due to frequent late diagnosis and poor treatment options." | ( Rabjerg, M, 2017) |
| "Axitinib activity in renal cell carcinoma (RCC) patients has been studied in various settings and particularly as second-line treatment." | ( Alexandre, J; Bellesoeur, A; Carton, E; Goldwasser, F; Huillard, O, 2017) |
| "69 patients with metastatic renal cell carcinoma had dynamic contrast-enhanced CT scans at baseline and after 5 and 10 weeks of treatment." | ( Donskov, F; Madsen, HHT; Mains, JR; Pedersen, EM; Rasmussen, F; Thorup, K; Thygesen, J, 2018) |
| "The outlook for patients with advanced renal cell cancer (RCC) has been improved by targeted agents including inhibitors of the PI3 kinase (PI3K)-AKT-mTOR axis, although treatment resistance is a major problem." | ( Anderson, C; Earwaker, P; Harris, AL; Macaulay, VM; Protheroe, AS; Willenbrock, F, 2018) |
| "He had a past medical history of renal cell carcinoma and had just started treatment with temsirolimus, a mammalian target of rapamycin (mTOR) inhibitor." | ( Fujioka, N; Iijima, Y; Kakizaki, Y; Kobayashi, Y; Miyashita, Y; Tsutsui, T; Uchida, Y, 2018) |
| "Anti-proliferative effect of SB in renal cell carcinoma (RCC) cell line UOK146 was evaluated by MTT assay and morphological characteristics were observed by phase contrast microscopy which displayed the cell death after SB treatment." | ( Agarwal, A; Das, P; Verma, SP, 2018) |
| "mTOR inhibitors are used to treat renal cell carcinoma (RCC)." | ( Algaba, F; Anguera, G; Apellániz-Ruiz, M; Boonman, J; Cascón, A; Maroto, P; Montero-Conde, C; Nellist, M; Robledo, M; Rodríguez-Antona, C; Roldan-Romero, JM, 2018) |
| "Prognostic biomarkers for patients with clear cell renal cell carcinoma (ccRCC), particularly those receiving therapy targeting angiogenesis, are not well established." | ( Cao, YW; Dong, Z; Guo, L; Kang, EH; Liu, Y; Niu, HT; Wang, YH; Zhang, W, 2018) |
| "Clear cell renal cell carcinoma (ccRCC) is the most common type of renal cell carcinoma, and anti-angiogenic treatment is currently first line therapy for metastatic ccRCC (mccRCC)." | ( Akslen, LA; Beisland, C; Bostad, L; Edelmann, RJ; Pilskog, M; Straume, O, 2018) |
| "Pazopanib is an approved treatment for renal cell carcinoma and a second-line treatment for nonadipocytic soft-tissue sarcoma." | ( Baich, TM; Derbala, MH; Guo, AS; Ho, TH; Justice, CN; Kempton, AN; Smith, SA, 2018) |
| "In a series of metastatic renal cell carcinoma (mRCC) patients treated with sunitinib, we aimed to study the correlation between hypothyroidism and single nucleotide polymorphisms (SNPs) in genes involved in sunitinib pharmacokinetics and pharmacodynamics." | ( Bastin, J; Bechter, O; Beuselinck, B; Debruyne, PR; Decallonne, B; Lambrechts, D; Lerut, E; Machiels, JP; Richard, V; Schöffski, P; Van Brussel, T; Verbiest, A; Verschaeve, V; Werbrouck, E; Wolter, P, 2019) |
| "Data on 634 patients with metastatic renal cell carcinoma treated with first-line sunitinib have been obtained." | ( Atzori, F; Bersanelli, M; Biasco, E; Buti, S; Carlo-Stella, G; Cossu Rocca, M; De Giorgi, U; De Lisi, D; Facchini, G; Fornarini, G; Galli, L; Guida, A; Iacovelli, R; Lolli, C; Masini, C; Massari, F; Miggiano, C; Mosca, A; Nobili, E; Nolè, F; Pastorino, A; Pinto, C; Porta, C; Ricotta, R; Rossetti, S; Sabbatini, R; Santini, D; Scartozzi, M; Terrone, C; Tortora, G; Toscani, I; Zucali, P, 2018) |
| "Imaging plays a key role throughout the renal cell carcinoma (RCC) patient pathway, from diagnosis and staging of the disease, to the assessment of response to therapy." | ( Goh, V; Kelly-Morland, C; Prezzi, D; Rossi, SH, 2018) |
| "Patients with metastatic renal cell cancer (mRCC) previously treated with agents targeting the vascular endothelial growth factor pathway were eligible to receive nivolumab 3 mg/kg once every 2 weeks." | ( Basso, U; Bearz, A; Berruti, A; Bracarda, S; Buti, S; Cartenì, G; Caserta, C; Cognetti, F; Cortesi, E; De Giorgi, U; Fornarini, G; Galli, L; Giannarelli, D; Lo Re, G; Pignata, S; Porta, C; Procopio, G; Rastelli, F; Sabbatini, R; Sternberg, CN; Turci, D, 2019) |
| "We present here a case of renal cell carcinoma who received successive treatment with sunitinib, everolimus, and axitinib." | ( Cil, I; Dulgar, O; Tural, D; Zirtiloglu, A, 2019) |
| "Seven patients with clear cell renal cell carcinoma received this combination treatment." | ( Fujiwara, Y; Ikezawa, H; Matsubara, N; Naito, Y; Nakano, K; Namiki, M; Okude, T; Takahashi, S; Yusa, W, 2018) |
| "sunitinib/sorafenib to treat metastatic renal cell carcinoma were analyzed under the proposed methods to illustrate their performance on real data." | ( Kim, J; Kim, S; Nam, CM, 2018) |
| "Case 1 and Case 2 had metastases of renal carcinoma at initial diagnosis and were treated with vascular endothelial growth factor receptors tyrosine kinase inhibitors." | ( Attignon, V; Carrie, C; Guerin, N; Haddad, V; Moriceau, G; Négrier, S; Pissaloux, D, 2018) |
| "Agarose encapsulated murine renal adenocarcinoma cells (RENCA macrobeads) are currently being investigated in clinical trials as a treatment for therapy-resistant metastatic colorectal cancer." | ( Bemrose, MA; Dudley, AT; Gazda, HL; Gazda, LS; Martis, PC; Smith, BH, 2018) |
| "For the treatment of metastatic renal cell cancer several strategies are used among which the mTOR inhibitor everolimus." | ( Bodalal, Z; de Gruijl, TD; Haanen, JB; Hamberg, P; Huijts, CM; Lougheed, SM; Tascilar, M; van der Vliet, HJ; van Herpen, CM; Verheul, HM, 2019) |
| "The treatment paradigm of advanced renal cell carcinoma (RCC) has changed rapidly in recent years." | ( Goldstein, DA; Leshno, M; Moore, A; Neiman, V; Reinhorn, D; Rosenbaum, E; Sarfaty, M, 2019) |
| "Clear cell renal cell carcinoma (ccRCC) expresses mutant von Hippel-Lindau gene and is difficult to treat." | ( Hsu, RJ; Pan, YR; Wei, CW; Wu, CY; Wu, TK; Yu, YL, 2019) |
| "Metastatic renal cell carcinoma patients treated with sunitinib between 1 July 2007 and 1 July 2011 at our institution." | ( Cheng, W; de Lemos, M; Kletas, V; Kollmannsberger, C, 2020) |
| "Clear cell renal cell carcinoma (ccRCC) is the most common type among renal cell carcinomas, and anti-angiogenic treatment is currently first line therapy in metastatic ccRCC (mccRCC)." | ( Beisland, C; Nilsen, GH; Pilskog, M; Straume, O, 2019) |
| "Patients with metastatic clear cell renal cell carcinoma (n = 71) with IMDC intermediate risk who received tyrosine kinase inhibitors as first-line therapy were included in this retrospective study." | ( Fukuda, H; Iizuka, J; Ishida, H; Ishihara, H; Kobayashi, H; Kondo, T; Okumi, M; Takagi, T; Tanabe, K; Yoshida, K, 2019) |
| "A 60-year-old man with metastatic renal cell carcinoma was treated with sunitinib." | ( Akar, E; Şahin, T; Tural, D; Yücel, MH, 2019) |
| "A 72-year-old male was diagnosed with renal cell carcinoma, for which everolimus was administered after unsuccessful treatment with sunitinib and sorafenib." | ( Haruki, K; Masubuchi, M; Saito, R; Tsunematsu, M; Watanabe, M; Yanaga, K, 2019) |
| "Using the International Metastatic Renal Cell Carcinoma Database Consortium (imdc) dataset, a retrospective analysis of patients with metastatic renal cell carcinoma (mrcc) treated with nivolumab or cabozantinib in the second line after prior therapy targeted to the vascular endothelial growth factor receptor (vegfr) was performed." | ( Agarwal, N; Alva, AS; Beuselinck, B; Bjarnason, GA; Choueiri, TK; Davis, ID; Donskov, F; Ernst, DS; Fu, SYF; Graham, J; Hansen, AR; Heng, DYC; Kanesvaran, R; Kollmansberger, C; Le, T; Srinivas, S; Stukalin, I; Wells, JC; Wood, LA; Yuasa, T, 2019) |
| "100 patients with metastatic clear cell renal cell carcinoma were treated with sunitinib in this study." | ( Bartnik, E; Brodziak, A; Czarnecka, AM; Dendek, C; Korniluk, J; Labochka, D; Sobczuk, P; Szczylik, C, 2019) |
| "A 77-year-old-man with renal cell carcinoma who was undergoing nivolumab treatment visited our department due to hyperglycemia; his plasma glucose level was 379 mg/dL." | ( Arioka, H; Hirose, R; Hoshino, Y; Ichikawa, M; Katsuragawa, S; Kubo, H; Nishikawa, T; Saitou, J; Sunouchi, T; Takiguchi, T; Tsurutani, Y; Yamamoto, N; Yukawa, H, 2019) |
| "In first-line treatment of advanced renal cell carcinoma (aRCC), the KEYNOTE-426 study demonstrated a significant progression-free survival and overall survival for pembrolizumab plus axitinib in comparison with sunitinib." | ( Chen, J; Chen, Z; Cheng, Z; Hu, G; Tan, C; Wan, X; Zeng, X, 2019) |
| "We evaluated outcomes of advanced renal cell carcinoma patients presenting with aggressive features when treated with temsirolimus or pazopanib as first-line therapy." | ( Chandramohan, A; Corn, PG; Devine, CE; Gonzalez, GMN; Karam, JA; Lim, ZD; Msaouel, P; Pruitt, L; Ross, JA; Tannir, NM; Wang, J; Wang, X; Wood, CG; Zurita, AJ, 2020) |
| "The treatment landscape in metastatic renal cell carcinoma has changed fundamentally over the last decade by the development of antiangiogenic agents, mammalian target of rapamycin inhibitors and immunotherapy." | ( Abadie-Lacourtoisie, S; Boughalem, E; Campillo-Gimenez, B; Chatellier, T; Cheneau, C; Cojocarasu, O; Coquan, E; Cumin, I; Deguiral, P; Delecroix, V; Delva, R; Déniel Lagadec, D; Desclos, H; Dupuy, S; Elhannani, C; Elkouri, C; Grudé, F; Hasbini, A; Joly, F; L'Haridon, T; Laguerre, B; Le Rol, A; Ligeza-Poisson, C; Malhaire, JP; Marhuenda, F; Merrer, J; Moise, L; Mollon, D; Monpetit, E; Pfister, C; Priou, F; Rolland, F; Schlürmann, F; Sevin, E; Tessereau, JY; Vauléon, E; Voog, E, 2020) |
| "The treatment of renal cell carcinoma has achieved certain curative effects with the innovation of clinical drugs, such as sunitinib." | ( Chen, C; Fang, H; Guo, Q; Jiao, Y; Lv, Z; Zhou, Y, 2019) |
| "A 26-year old male with metastatic clear cell renal cell carcinoma was started on treatment with the anti-programmed cell death-1 monoclonal antibody (anti-PD-1 mAb) nivolumab, followed by combined nivolumab and the anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) mAb, ipilimumab." | ( Gallagher, EJ; Galsky, M; Leiter, A; Thapi, S, 2019) |
| "Patients with metastatic renal carcinoma frequently have pre-existing renal impairment and not infrequently develop worsening renal function as a complication of their treatment." | ( Chamberlain, S; Mole, DR; Protheroe, A; Purshouse, K; Soares, M; Tuthill, M, 2019) |
| "However, the roles of LAT1 in renal cell carcinoma (RCC) prognosis and treatment remain uncharacterized." | ( Ando, K; Anzai, N; Furihata, T; Higuchi, K; Ichikawa, T; Ikehara, Y; Imamura, Y; Maimaiti, M; Matsushima, J; Nakamura, K; Okunushi, K; Reien, Y; Sakamoto, S; Sazuka, T; Takeshita, N, 2019) |
| "The treatment landscape for metastatic renal cell carcinoma (mRCC) and urothelial carcinoma (mUC) has evolved rapidly in recent years with the approval of several checkpoint inhibitors." | ( Bergerot, P; Lamb, P; Pal, SK; Wang, E, 2019) |
| "Treatment for renal cell carcinoma has been revolutionised by inhibitors of VEGF receptor." | ( Atkins, MB; Escudier, BJ; Hutson, TE; McDermott, DF; Needle, MN; Pal, SK; Porta, C; Rini, BI; Verzoni, E, 2020) |
| "Early diagnosis of renal cell carcinoma is extremely significant for the effective treatment of kidney cancer." | ( Bai, H; Cai, L; Dong, L; He, M; Li, J; Wang, Q; Xu, K; Zhang, M; Zhao, M; Zheng, S, 2019) |
| "International Metastatic Renal Cell Carcinoma (mRCC) Database Consortium (IMDC) risk groups are important when considering therapeutic options for first-line treatment." | ( Bjarnason, GA; Chang, R; Donskov, F; Dudani, S; Duh, MS; Graham, J; Hansen, AR; Heng, DYC; Huynh, L; Iafolla, MAJ; McGregor, BA; Savard, MF; Steinharter, JA; Vaishampayan, UN; Wells, JC; Zanotti, G, 2020) |
| "Clear cell renal cell carcinoma is the most common in all of the renal cancers; however, it lacks ideal molecular target for treatment." | ( Hu, X; Jia, M; Li, J; Qiu, W; Su, M; Wang, S; Xu, Y, 2020) |
| "Current treatments for clear cell renal cell cancer (ccRCC) are insufficient because two-thirds of patients with metastases progress within two years." | ( Bauer, D; Birchmeier, W; Busch, J; Chen, W; Elezkurtaj, S; Erguen, B; Fendler, A; Jung, K; Jung, S; Kunz, S; Myszczyszyn, A; Song, K; Wulf-Goldenberg, A, 2020) |
| "Patients diagnosed with non-clear renal cell carcinoma have often been excluded from clinical trials due to the shortage of treatments available, the low incidence of tumours with non-clear histology, and the corresponding diversity of intrinsic molecular features." | ( Bagby, S; Chirra, M; D'Angelo, A; Di Pierro, G; Mini, E; Nobili, S; Roviello, G; Villari, D, 2020) |
| "Patients with metastatic renal cell cancer (mRCC) are commonly treated with the tyrosine kinase inhibitor sunitinib, which blocks signalling from vascular endothelial growth factor (VEGF) - and platelet-derived growth factor-receptors, inhibiting development of new blood vessels." | ( Dimberg, A; Enblad, G; Georganaki, M; Lindskog, C; Niinivirta, M; Ullenhag, GJ, 2020) |
| "In a set of genetically distinct human renal cell carcinoma (RCC) cell lines, either treated chronically with sunitinib (-ST) or sunitinib-naive, we identified cell line-specific low-dose-optimised drug combinations (ODC)." | ( Achkhanian, J; Nowak-Sliwinska, P; Rausch, M; Rotari, A; Weiss, A, 2020) |
| "Non-clear cell renal cell cancers (nccRCC) are rare entities, and the optimal therapy in metastatic disease has still to be defined." | ( Bergmann, L; Flörcken, A; Gauler, T; Greiner, J; Grimm, MO; Grünwald, V; Hartmann, A; Klotz, T; Maute, L; Schleicher, J; Weikert, S, 2020) |
| "The treatment of renal cell carcinoma (RCC) with chemotherapy remains a challenge; therefore, improving the knowledge of the molecular mechanisms underlying RCC chemoresistance and developing novel therapeutic strategies is important." | ( Cai, Y; Chen, W; Lu, X; Mao, J; Ni, H; Xie, L; Xie, S; Zhang, S; Zhang, W; Zheng, X, 2020) |
| "Patients with metastatic renal cell carcinoma (mRCC) treated with targeted systemic therapies have demonstrated favourable outcomes in randomised controlled trials, however real-world evidence is limited." | ( Eisen, T; Fife, K; Gordon, J; Hawkins, R; Hurst, M; Matakidou, A; Naicker, N; Nolasco, S; Wang, M, 2020) |
| "Cases of patients with renal cell carcinoma refractory to checkpoint inhibitor treatment are growing, warranting a review of the activity and safety of target therapies after immunotherapy." | ( Barzaghi, P; Perego, G; Petrelli, F; Vavassori, I, 2020) |
| "Patients with advanced renal cell carcinoma with sarcomatoid features (sRCC) have poor prognoses and suboptimal outcomes with targeted therapy." | ( Barthélémy, P; Choueiri, TK; Donskov, F; Ficial, M; Flaifel, A; Frontera, OA; George, S; Harrison, MR; Ishii, Y; Kocsis, J; McDermott, DF; McHenry, MB; Motzer, RJ; Murad, AM; Pal, SK; Pignon, JC; Powles, T; Ravaud, A; Rini, BI; Rodriguez-Cid, JR; Saggi, SS; Signoretti, S; Tannir, NM; Tykodi, SS, 2021) |
| "In this real-world study, metastatic renal cell cancer patients treated with first-line pazopanib reached greater progression-free survival and overall survival than in pivotal studies and had high response rates when belonging to International Metastatic RCC Database Consortium's favorable group, without new toxicities." | ( Basso, U; Bersanelli, M; Boccardo, F; Caffo, O; Cartenì, G; De Giorgi, U; Fornarini, G; Galli, L; Mosca, A; Naglieri, E; Porta, C; Procopio, G, 2021) |
| "Metastatic clear cell renal cell carcinoma (mccRCC) benefits from several treatment options in the first-line setting with VEGFR inhibitors and/or immunotherapy including anti-PD-L1 or anti-PD1 agents." | ( Ambrosetti, D; Borchiellini, D; Chamorey, E; Dufies, M; Ferrero, JM; Hagege, A; Iovanna, J; Montemagno, C; Negrier, S; Pagès, G; Porta, C; Rastoin, O; Rioux-Leclercq, N; Thamphya, B, 2020) |
| "Targeted therapy for metastatic renal cell carcinoma (mRCC) treatment requires the identification of clinically important factors that can predict the therapeutic effect." | ( Chung, JI; Ha, HK; Kim, W; Ku, JY; Lee, CH; Park, TY; Park, YJ; Seo, WI, 2021) |
| "Determining the aggressiveness of renal cell carcinoma (RCC) noninvasively is a critical part of the diagnostic workup for treating this disease that kills more than 15,000 people annually in the USA." | ( Ahamed, F; Kurhanewicz, J; Larson, P; Sriram, R; Van Criekinge, M; Wang, ZJ, 2021) |
| "The treatment landscape of metastatic clear cell renal cell carcinoma (mccRCC) has been transformed by targeted therapies with tyrosine kinase inhibitors (TKI) and more recently by the incorporation of immune checkpoint inhibitors (ICI)." | ( Aeppli, S; Eisen, T; Escudier, B; Grünwald, V; Larkin, J; McDermott, D; Oldenburg, J; Porta, C; Putora, PM; Rini, BI; Rothermundt, C; Schmaus, M; Schmidinger, M; Sternberg, CN, 2021) |
| "However, in the case of metastasis Renal Cell Cancer (mRCC), which showed a good response to sunitinib, we found that long-term treatment with sunitinib could promote lysosome biosynthesis and exocytosis, thereby triggering the metastasis of RCC." | ( Fan, Y; Li, L; Liu, C; Liu, J; Liu, Z; Pang, S; Zhang, N; Zhao, S, 2021) |
| "In metastatic (clear cell) renal cell carcinoma (RCC), ICI was first introduced as second-line treatment after vascular endothelial growth factor receptor-tyrosine kinase inhibition (VEGFR-TKI)." | ( Alberts, AR; Iflé, IG; Scholtes, MP; van der Veldt, AAM; Verhagen, PCMS; Zuiverloon, TCM, 2021) |
| "Advanced non-clear cell renal cell carcinoma (nccRCC) has a poor prognosis and clinical data on the therapeutic options currently available, including immunotherapy, are generally limited highlighting an unmet clinical need." | ( Borea, R; Catalano, F; Damassi, A; Fornarini, G; Martelli, V; Murianni, V; Rebuzzi, SE; Rollandi, GA, 2022) |
| "The Metastatic Renal Cell Carcinoma (MaRCC) Registry provides prospective data on real-world treatment patterns and outcomes in patients with metastatic renal cell carcinoma (mRCC)." | ( Agarwal, N; Appleman, LJ; Bhavsar, NA; Borham, A; Costello, BA; Fishman, MN; Gartrell, BA; George, DJ; Hammers, HJ; Harrison, MR; Hussain, A; Hutson, TE; Jim, H; Kyriakopoulos, CE; Mardekian, J; Molina, AM; Pachynski, RK; Pal, SK; Ryan, CW; Stadler, WM; Tsao, CK; Vaishampayan, U; Zakharia, Y, 2022) |
| "Patients with metastatic renal cell carcinoma treated with the 2/1 schedule of sunitinib, whose total sunitinib concentrations were available, were recruited for this study." | ( Fujisawa, M; Furukawa, J; Harada, K; Ito, T; Omura, T; Yamamoto, K; Yano, I, 2022) |
| "Patients with brain metastases from renal cell carcinoma (RCC) have been underrepresented in clinical trials, and effective systemic therapy is lacking." | ( Abuqayas, B; Agarwal, N; Albigès, L; Barthélémy, P; Beuselinck, B; Bilen, MA; Bowman, IA; Brastianos, PK; Braun, DA; Choueiri, TK; Collier, KA; de Velasco, G; Dzimitrowicz, H; Farah, S; Flippot, R; Harrison, MR; Harshman, LC; Hirsch, L; Krajewski, KM; Lam, ET; Martinez Chanza, N; McKay, RR; Mortazavi, A; Rathi, N; Seront, E; Thouvenin, J; Varkaris, A; Xie, W; Xu, W; Zakharia, Y, 2021) |
| "Treatment options for metastatic renal cell carcinoma (mRCC) and metastatic urothelial carcinoma (mUC) have increased dramatically over the past decade." | ( Favorito, C; Malhotra, J; Meza, L; Pal, SK, 2022) |
| "Adult patients with untreated advanced renal cell carcinoma (RCC) with a clear-cell component, ≥1 measurable lesions, Eastern Cooperative Oncology Group performance status of 0 or 1, fresh or archival tumor specimen, and adequate renal, cardiac, and hepatic function were included." | ( Albiges, L; Bilen, MA; Choueiri, TK; di Pietro, A; Haanen, JBAG; Huang, B; Kislov, N; Krulewicz, S; Lalani, AA; Lam, ET; Larkin, J; McGregor, BA; Pagliaro, LC; Rini, BI; Robbins, PB; Voog, EG; Voss, MH, 2022) |
| "In patients with renal cell carcinoma, pazopanib treatment requires clinical caution as it causes rare complications such as severe jaundice and acute cholestatic hepatitis." | ( Chin, S; Choi, JW; Kim, SG; Kim, YS; Yoo, JJ, 2021) |
| "In vitro, two sunitinib-resistant renal cell carcinoma cell lines (Caki-1 and SN12K1) were treated with tocilizumab." | ( Gobe, GC; Kamli, H; Li, L; Morais, C; Owens, EP; Prasanna, R; Vesey, DA, 2022) |
| "In the treatment of advanced renal cell carcinoma, anti-VEGFR tyrosine kinase inhibitors (TKI) have been replaced mostly by immunotherapy combinations with checkpoint inhibitors (CPI), especially in first line therapy." | ( Bergmann, L; Doehn, C; Grünwald, V; Gschwend, JE; Ivanyi, P; Kuczyk, MA; Miller, K, 2022) |
| "A 79-year old male with metastatic papillary renal cell carcinoma and malignant ascites was treated with pazopanib." | ( Krens, SD; Mulder, SF; van Erp, NP, 2022) |
| "We present the case of a metastatic renal cell carcinoma patient treated with standard Sunitinib dosing (i." | ( Chauvin, J; Ciccolini, J; Deville, JL; Ferrer, F, 2022) |
| "Advanced renal cell carcinoma (RCC) is a difficult-to-treat disease with a poor prognosis." | ( Markham, A, 2022) |
| "Metastatic collecting duct carcinoma (mCDC) is a rare type of non-clear cell renal cell carcinoma (ncRCC) with poor prognosis and no standard treatments." | ( Buti, S; Claps, M; Colecchia, M; de Braud, F; Fucà, G; Giannatempo, P; Guadalupi, V; Lalli, L; Mariani, L; Procopio, G; Sepe, P; Verzoni, E, 2022) |
| "The treatment landscape in metastatic renal cell carcinoma (mRCC) has evolved dramatically in recent years." | ( Bergmann, L; Brehmer, B; Eberhardt, B; Gauler, T; Gehbauer, G; Grünwald, V; Gschwend, J; Johannsen, M; Kastrati, K; Klotz, T; Protzel, C; Schenck, M; Staehler, M, 2022) |
| "Papillary renal cell carcinoma (PRCC) represents 15% of RCCs but has no indicated therapies, with limited biomarker-based data to inform targeted treatment." | ( Albiges, L; Cancel, M; Choueiri, T; Frigault, MM; Heng, DYC; L'Hernault, A; Lee, JL; Mellemgaard, A; Ottesen, L; Signoretti, S; Walker, S; Wessen, J, 2022) |
| "Treatment paradigm for metastatic clear cell renal cell carcinoma (mccRCC) has changed dramatically over the recent decades." | ( Choueiri, TK; Gulati, S; Karachaliou, GS; Labaki, C; Zhang, T, 2022) |
| "Blood was collected from 20 metastatic renal cell carcinoma (mRCC) patients before treatment, and at 2 weeks, 4 weeks and 3 months after sunitinib administration." | ( Aarts, MJB; Brouns, SLN; de Bruijn, P; Heemskerk, JWM; Koolen, SLW; Kuijpers, MJE; Peters, NAJB; Sabrkhany, S; Swieringa, F; Tullemans, BME; van den Berkmortel, FWPJ, 2022) |
| "In this review, we explain renal cell carcinoma and its different types of treatment by the anti-renal carcinoma drugs." | ( Billowria, K; Chawla, PA; Kumar, B; Passi, I, 2023) |
| "Patients with advanced renal cell carcinoma and poor performance status (PS≥2) are often deemed unsuitable for treatment." | ( Farrugia, D; Fife, K; Hodgkins, AM; MacDonald-Smith, C; Pirrie, S; Porfiri, E; Stubbs, C; Vasudev, N; Zarkar, A, 2022) |
| "The poor sensitivity of clear cell renal cell carcinoma (ccRCC) to conventional chemotherapy and radiotherapy makes its treatment challenging." | ( Chen, X; Chen, Y; Li, Z; Lin, J; Min, S; Xie, X; Yu, H, 2022) |
| "A 47-year-old woman (Case 1) with renal cell carcinoma developed severe headache after a seventh nivolumab administration." | ( Hanaoka, T; Jikumaru, M; Kimura, N; Masuda, T; Matsubara, E; Mizukami, T; Uchida, H, 2022) |
| "everolimus in patients with advanced clear cell renal cell carcinoma (ccRCC) that had progressed on or after VEGF-targeted therapy." | ( Castellano, D; Chen, J; Choueiri, TK; Czaykowski, P; Duran, I; Hainsworth, J; Porta, C; Powles, T; Reeves, J; Sedarati, F; Suárez, C; Voog, E, 2022) |
| "The treatment landscape of metastatic renal cell carcinoma (RCC) has significantly evolved in recent years with the advent and approval of multiple combinations of anti-angiogenic agents with immune checkpoint inhibitors, of which the combination of lenvatinib plus pembrolizumab is the most recent to be incorporated into clinical practice." | ( Ged, Y; Lee, CH, 2022) |
| "Treatment of metastatic renal cell carcinoma (mRCC) is rapidly evolving with new combination therapies demonstrating improved response rates and survival." | ( Anari, F; Geynisman, DM; Ghatalia, P; Handorf, E; Miron, B; Plimack, ER; Zarrabi, KK; Zibelman, MR, 2023) |
| "Clear cell renal cell carcinoma (ccRCC) is a common malignant tumor of the urinary system characterized by poor prognosis and difficult treatment." | ( Bi, Q; Cao, H; Hao, C; Sun, Z; Wang, W; Wu, J; Zheng, X, 2022) |
| "Clear cell renal cell carcinoma (ccRCC) is a common malignant tumor of the urinary system characterized by poor prognosis and difficult treatment." | ( Bi, Q; Cao, H; Hao, C; Sun, Z; Wang, W; Wu, J; Zheng, X, 2022) |
| "Clear cell renal cell carcinoma (ccRCC) is a common malignant tumor of the urinary system characterized by poor prognosis and difficult treatment." | ( Bi, Q; Cao, H; Hao, C; Sun, Z; Wang, W; Wu, J; Zheng, X, 2022) |
| "Tissues of renal cell carcinoma (RCC) patients treated with VEGF pathway-targeted drugs and control tissues were subject to RNAseq and immunohistochemical profiling of the leukocyte infiltrate." | ( Bernards, R; Bex, A; de Gruijl, TD; Dings, RPM; Griffioen, AW; Griffioen, CJ; Groenendijk, FH; Huijbers, EJM; Huinen, ZR; Jenkins, SV; Jonasch, E; Jordanova, ES; Nowak-Sliwinska, P; Schulz, R; Sopesens, NG; Thijssen, VLJL; van Beijnum, JR; Vyth-Dreese, FA, 2023) |
| "Tissues of renal cell carcinoma (RCC) patients treated with VEGF pathway-targeted drugs and control tissues were subject to RNAseq and immunohistochemical profiling of the leukocyte infiltrate." | ( Bernards, R; Bex, A; de Gruijl, TD; Dings, RPM; Griffioen, AW; Griffioen, CJ; Groenendijk, FH; Huijbers, EJM; Huinen, ZR; Jenkins, SV; Jonasch, E; Jordanova, ES; Nowak-Sliwinska, P; Schulz, R; Sopesens, NG; Thijssen, VLJL; van Beijnum, JR; Vyth-Dreese, FA, 2023) |
| "Many drugs are available in renal cell carcinoma (RCC), yet clinicians are still looking for predictive biomarkers of disease recurrence or progression supporting more personalised treatments." | ( Albiges, L; Badoual, C; Benhamouda, N; Cessot, A; Fournier, L; Galy-Fauroux, I; Guillot, A; Helley, D; Le Moulec, S; Mauge, L; Mejean, A; Oudard, S; Phan, L; Tartour, E; Thiery-Vuillemin, A; Topart, D, 2023) |
| "Many drugs are available in renal cell carcinoma (RCC), yet clinicians are still looking for predictive biomarkers of disease recurrence or progression supporting more personalised treatments." | ( Albiges, L; Badoual, C; Benhamouda, N; Cessot, A; Fournier, L; Galy-Fauroux, I; Guillot, A; Helley, D; Le Moulec, S; Mauge, L; Mejean, A; Oudard, S; Phan, L; Tartour, E; Thiery-Vuillemin, A; Topart, D, 2023) |
| "Advanced renal cell carcinoma (RCC) remains a challenging oncologic disease to treat despite advancements in therapeutics." | ( Benjamin, DJ; Cella, D; Nolla, K, 2022) |
| "Treatment for advanced renal cell carcinoma (aRCC) comprises single agent or combinations of immune checkpoint inhibitors and/or anti-angiogenic agents." | ( Alam, S; Ghosh-Ray, S; Gogbashian, A; Lakhani, A; Nathan, P; Padhani, A; Sharma, A, 2023) |
| "Papillary renal cell cancer is a rare malignancy with limited treatment options in the advanced stage of the disease." | ( Civan, C; Isik, EG; Karadogan, S; Kuyumcu, S; Sanli, Y, 2023) |
| "The treatment landscape for metastatic renal cell carcinoma (mRCC) has significantly evolved in recent years." | ( Adashek, JJ; Byrne, MM; Chadha, J; Chahoud, J; Gilbert, SM; Jim, HSL; Joshi, VB; Kim, Y; Manley, BJ; Mason, NT; Schneider, AM; Shah, SS; Spiess, PE, 2023) |
| "Patients with clear-cell advanced renal cell carcinoma who had not received any systemic anticancer therapy for renal cell carcinoma, including anti-vascular endothelial growth factor therapy, or any systemic investigational anticancer drug, were eligible for inclusion from 200 sites (hospitals and cancer centres) across 20 countries." | ( Alekseev, B; Alemany, C; Alonso Gordoa, T; Basappa, NS; Buchler, T; Choueiri, TK; De Giorgi, U; Eto, M; Goh, JC; Grünwald, V; Hoon Park, S; Hutson, T; Kapoor, A; Kopyltsov, E; McGregor, B; McKenzie, J; Melichar, B; Méndez-Vidal, MJ; Merchan, JR; Mody, K; Motzer, R; Perini, RF; Porta, CG; Powles, T; Rha, SY; Staehler, M; Tjulandin, S; Xie, R, 2023) |
| "A total of 64 patients with renal cell carcinoma were divided into the observation group (nursing based on oxygen administration) and the control group (conventional nursing)." | ( Sha, R; Shi, J; Yang, X, 2023) |
| "Clear cell renal cell carcinoma (ccRCC) has poor clinical outcomes and necessitates new treatment options." | ( Liu, D; Xu, M; Zhou, G, 2023) |
| "Since renal cell carcinoma(RCC) is insensitive to conventional chemoradiotherapy, molecularly targeted drugs are commonly used treatments for unresectable advanced RCC." | ( Fan, L; Lu, H; Xia, X; Ye, Q; Zheng, C, 2023) |
| "Metastatic renal cell carcinoma (mRCC) treatment is still largely based on TKI use." | ( Banna, GL; Brighi, N; Brunelli, M; Buti, S; Caffo, O; Cattrini, C; Corianò, M; De Giorgi, U; Fornarini, G; Giannarelli, D; Giudice, GC; Kinspergher, S; Malgeri, A; Mennitto, A; Puglisi, S; Rametta, A; Rebuzzi, SE; Roviello, G; Santoni, M; Scartabellati, G; Signori, A; Stellato, M; Tommasi, C; Verzoni, E, 2023) |
| "In patients with advanced clear cell renal cell carcinoma, despite the undoubted benefits from immune checkpoint inhibitor (ICI)-based therapies over monotherapies of angiogenic/mTOR inhibitors in the intention-to-treat population, approximately a quarter of the patients can scarcely gain advantage from ICIs, prompting the search for predictive biomarkers for patient selection." | ( Cai, S; Huang, Y; Liu, K; Shi, T; Wang, G; Xu, Y; Zhang, X, 2023) |
| "Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer and is notorious for its resistance to both chemotherapy and small-molecule inhibitor targeted therapies." | ( Chu, GC; Chung, LWK; Edderkaoui, M; Heffer, M; Lewis, MS; Mrdenovic, S; Ou, Y; Pandol, SJ; Posadas, EM; Wang, R; Wang, Y; Yin, L; Zhang, Y; Zhau, HE, 2023) |
| "Clear cell renal cell carcinoma (ccRCC) displays sex-biased incidence, outcomes, molecular alterations and treatment efficacy; however, clinical managements are largely identical in male and female patients." | ( Fan, Y; Fang, Z; Liu, L; Qin, X; Xu, D; Yang, Q; Yuan, H, 2023) |
| "Many types of cancer including clear cell renal cell carcinoma (ccRCC) are known to display sex-biased survival, genomic alterations and treatment efficacy; however, clinical managements are largely identical in male and female ccRCC patients." | ( Fan, Y; Fang, Z; Liu, L; Qin, X; Xu, D; Yang, Q; Yuan, H, 2023) |
| "In advanced Renal Cell Carcinoma (aRCC), systemic therapy is the mainstay of treatment, with no or little role for surgery in these patients." | ( Agarwal, S; Agarwal, V; Barkate, H; Batra, S; Bhagat, S; Biswas, G; Dattatreya, PS; Desai, C; Deshmukh, C; Dhabhar, B; Mohapatra, PN; Patil, S; Philip, A; Rauthan, A; Saha, R; Sahoo, TP, 2023) |
| "Multiple renal cell carcinoma (RCC) tumor models were then cotreated with both HC-5404 and VEGFR-TKI in vivo, measuring tumor volume across time and evaluating tumor response by protein analysis and IHC." | ( Ballal, N; Betzenhauser, M; Bose, N; Calvo, V; Dudgeon, C; Fujisawa, S; Gasparek, J; Huang, S; Lightcap, ES; Mulvihill, MJ; Rigby, AC; Shen, L; Staschke, KA; Stokes, ME; Surguladze, D; Taylor, SJ, 2023) |
| "The treatment landscape for metastatic renal cell carcinoma changed a lot in the last few years." | ( Chen, CS; Chiu, KY; Hung, SC; Lai, GS; Li, JR; Lin, CY; Wang, SS; Yang, CK; Yang, SF, 2023) |
| "We enrolled patients with metastatic renal cell carcinomawho received first-line systemic treatment with tyrosin kinase inhibitors monotherapy, ipilimumab plus nivolumab, or pembrolizumab plus axitinibbetween January2009 and May 2023 on the database of TriNetX network." | ( Chen, CS; Chiu, KY; Hung, SC; Lai, GS; Li, JR; Lin, CY; Wang, SS; Yang, CK; Yang, SF, 2023) |